<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Metab Target Organ Damage.</journal-id>
      <journal-id journal-id-type="publisher-id">mtod</journal-id>
      <journal-title-group>
        <journal-title>Metabolism and Target Organ Damage</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2769-6375</issn>
      <publisher>
        <publisher-name>OAE Publishing Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.20517/mtod.2025.190</article-id>
      <article-id pub-id-type="publisher-id">MTOD-2025-190</article-id>
      <article-categories>
        <subj-group>
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Macrophage ferroptosis in atherosclerosis: unraveling novel antiatherogenic targets and pharmacological strategies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shi</surname>
            <given-names>Jia</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
            <sup>1</sup>
          </xref>
		  <xref ref-type="aff" rid="I2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="I1035">
            <sup>#</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>Fangyang</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="I1035">
            <sup>#</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jida</given-names>
          </name>
          <xref ref-type="aff" rid="I3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="I1035">
            <sup>#</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Guobin</given-names>
          </name>
          <xref ref-type="aff" rid="I4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Runchen</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>Liping</given-names>
          </name>
          <xref ref-type="aff" rid="I2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Zhang</surname>
            <given-names>Xinyu</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Wang</surname>
            <given-names>Yizhou</given-names>
          </name>
          <xref ref-type="aff" rid="I2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Ma</surname>
            <given-names>Chuanrui</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="I1"><sup>1</sup>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, Tianjin 300193, China.</aff>
	  <aff id="I2"><sup>2</sup>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China.</aff>
      <aff id="I3"><sup>3</sup>School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.</aff>
      <aff id="I4"><sup>4</sup>NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital &amp; Institute of Endocrinology, Tianjin 300134, China.</aff>
      <aff id="I1035"><sup>#</sup>These authors contributed equally to this work.</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to: Dr. Chuanrui Ma, Dr. Xinyu Zhang, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, Tianjin 300193, China. E-mail: <email>chuanruima2013@mail.nankai.edu.cn</email>; <email>xinyuzhang@tjatcm.ac.cn</email>; Dr. Yizhou Wang, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China. E-mail: <email>yizhouwang@tjatcm.ac.cn</email></corresp>
        <fn fn-type="other">
          <p><bold>Received:</bold> 27 Oct 2025 | <bold>First Decision:</bold> 27 Jan 2026 | <bold>Revised:</bold> 29 Apr 2026 | <bold>Accepted:</bold> 30 Apr 2026 | <bold>Published:</bold> 16 Nov 2026</p>
        </fn>
        <fn fn-type="other">
          <p><bold>Academic Editor:</bold> Amedeo Lonardo | <bold>Copy Editor:</bold> Tong Wang | <bold>Production Editor:</bold> Tong Wang</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>11</month>
        <year>2026</year>
      </pub-date>
      <volume>6</volume>
	  <issue>4</issue>
      <elocation-id>70</elocation-id>
      <permissions>
        <copyright-statement>© The Author(s) 2026.</copyright-statement>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>© The Author(s) 2026.<bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Atherosclerosis is the underlying cause of many cardiovascular diseases, and macrophages play a pivotal role in its intricate landscape, significantly regulating inflammation, lipid metabolism, and iron metabolism. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation, and its process is related to macrophage function in atherosclerosis. During atherosclerosis, macrophages contribute to the removal of harmful substances such as lipids and inhibit early development. However, macrophage ferroptosis promotes inflammatory progression, facilitates foam cell and necrotic core formation, promotes calcification, and increases plaque instability. This review first summarizes macrophage heterogeneity in atherosclerosis, then integrates their roles in lipid handling and iron metabolism, and finally focuses on how ferroptosis shapes plaque inflammation, necrotic core formation, calcification, and instability. Currently, the pharmacologic treatment of atherosclerosis is based on lipid-lowering agents, but it remains deficient. Therefore, this review encompasses a variety of potential pharmacological treatments, including organic compounds, natural plant extracts and derivatives, and compound formulations, which can inhibit macrophage ferroptosis and may constitute a novel approach for atherosclerosis treatment. Taken together, this review provides a breakthrough strategy for treating atherosclerosis and establishes a navigational pathway for future therapeutic interventions by targeting macrophage ferroptosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Macrophages</kwd>
        <kwd>ferroptosis</kwd>
        <kwd>atherosclerosis</kwd>
        <kwd>inflammation</kwd>
        <kwd>therapeutics</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>INTRODUCTION</title>
      <p>Cardiovascular diseases (CVDs) are recognized globally for their high rates of mortality and disability<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>. Atherosclerosis, a chronic inflammatory disease, is a primary contributor to CVDs, characterized by lipid accumulation and immune system engagement<sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup>. Macrophages exert a dual effect during atherogenesis. In early lesions, they clear lipids and cellular debris, thereby providing protection<sup>[<xref ref-type="bibr" rid="B3">3</xref>]</sup>. However, when lipid uptake exceeds processing capacity, they transform into foam cells, amplify inflammation, and contribute to necrotic core formation<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup>. Consequently, maintaining normal phagocytosis of macrophages and preventing macrophage death emerge as strategies to mitigate atherosclerosis.</p>
      <p>Ferroptosis is a lipid peroxidation process driven by iron ions, distinct from other programmed cell death mechanisms<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup>, and studies have confirmed its role in accelerating atherosclerosis progression<sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup>. Excess intracellular iron promotes reactive oxygen species (ROS) generation via the Fenton reaction [in which Fe<sup>2+</sup> catalyzes H<sub>2</sub>O<sub>2</sub> to generate highly toxic hydroxyl radicals (·OH)], leading to lipid peroxidation of cellular membranes and ferroptosis. Macrophages play crucial roles in regulating inflammation, iron, and lipid metabolism in atherosclerosis due to their unique abilities in phagocytosis, cytotoxicity, and cytokine secretion<sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup>. During atherosclerosis, lipoproteins phagocytosed by macrophages increase the substrate for lipid peroxidation and facilitate the execution of ferroptosis. Furthermore, in this process, ROS production by macrophages is a key contributor to ferroptosis, pro-inflammatory polarization, and foam cell formation. During ferroptosis, the scavenging function of macrophages is diminished, leading to increased lipids and necrotic cells accumulation in atherosclerotic plaques. This, in turn, results in the formation and enlargement of necrotic cores<sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup>. In addition to ferroptosis, other types of cell death, such as apoptosis, autophagy, necroptosis, and pyroptosis, also occur in macrophages during the progression of atherosclerosis<sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup>. Regardless of the form of cell death, reduced clearance efficiency leads to the accumulation of dead cells and the formation of a necrotic core. This review focuses on ferroptosis, emphasizing its potential as a target for inhibiting the development of atherosclerosis.</p>
      <p>The prevailing pharmacologic strategies for reducing atherosclerosis primarily involve lipid-lowering drugs, predominantly statins, and their combinations. In recent years, trials have successfully reduced cardiovascular events with non-statin lipid-lowering agents, highlighting the expansion of lipid-lowering strategies<sup>[<xref ref-type="bibr" rid="B10">10</xref>]</sup>. These include monoclonal antibodies, small interfering RNAs (siRNAs)<sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup>, antisense oligonucleotides<sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup>, vaccinations<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup>, and other lipid-lowering therapies<sup>[<xref ref-type="bibr" rid="B14">14</xref>]</sup>, such as small-molecule inhibitors. However, these therapies are associated with adverse effects, such as myotoxicity, metabolic toxicity, nervous system damage, poor specificity, inadequate safety, and other possible side effects<sup>[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]</sup>. This led to an increased focus on identifying treatments with precise efficacy and minimal side effects in antiatherogenic research. Given that macrophages are involved in atherosclerosis and in ferroptosis, targeting macrophage ferroptosis represents a promising approach to treat atherosclerosis. Recent studies have identified various compound formulations and natural plant extracts that act on multiple pathways to attenuate macrophage ferroptosis, demonstrating their potential in atherosclerosis treatment.</p>
      <p>Accordingly, this review explores the connection between macrophage ferroptosis and atherosclerosis, highlighting drugs with anti-ferroptotic effects on macrophages to provide new insights for the treatment of atherosclerosis. Although ferroptosis has attracted attention in other diseases, in the context of atherosclerosis, the specific mechanism of macrophage ferroptosis, its impact on plaque stability, and potential therapies targeting ferroptosis remain urgent issues to be addressed.</p>
    </sec>
    <sec id="sec2">
      <title>MACROPHAGES IN THE PROGRESSION OF ATHEROSCLEROSIS</title>
      <sec id="sec2-1">
        <title>Polarization and plasticity of macrophages affect the development of atherosclerosis</title>
        <p>Macrophages are highly plastic innate immune cells that participate in nearly every stage of atherosclerosis, from monocyte recruitment and foam cell formation to plaque inflammation and repair<sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup>. Notably, macrophages are involved in almost all stages of atherosclerosis. Macrophages at atherosclerotic lesions are derived primarily from circulating recruited monocytes and vascular smooth muscle cells<sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup> [<xref ref-type="fig" rid="fig1">Figure 1</xref>]. Within plaques, macrophages display a spectrum of phenotypes rather than a binary M1/M2 state. Although M1 and M2 remain the best-characterized subsets, plaque microenvironments also induce oxidized phospholipid-induced macrophages (Mox), M4, hemoglobin-associated macrophages (M(Hb)), and heme-associated macrophages (Mhem) phenotypes, each with distinct inflammatory, lipid-handling, and iron-handling features. M1 macrophages promote inflammation and are activated by proinflammatory factors, including interferon-gamma (IFN-γ), tumor necrosis factor (TNF), oxidized low-density lipoprotein (ox-LDL), and lipopolysaccharide<sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup>. M2 macrophages are induced by interleukin-4 (IL-4) and IL-13, which play an anti-inflammatory and pro-tissue-repair role in the atherosclerotic process<sup>[<xref ref-type="bibr" rid="B20">20</xref>]</sup>. According to the differences in activators, M2 macrophages can be further categorized into four subtypes: M2a macrophages are activated by IL-13 and IL-4 and exert anti-inflammatory and pro-restorative effects; M2b macrophages are activated by immune complexes, IL-1β, and so on, and have immune regulatory effects; IL-10, transforming growth factor-beta (TGF-β), and glucocorticoids can activate M2c macrophages and promote tyrosine kinase Mer (MerTK)-mediated phagocytosis of apoptotic cells; Activation of M2d macrophages by ligands for Toll-like receptors (TLRs) and adenosine A2 receptor (A2a receptor) reduces pro-inflammatory factor production while also promote angiogenesis<sup>[<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]</sup>. Mox macrophages exert dual roles in atherogenesis; they exhibit antioxidant properties via nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated expression of antioxidant genes, but also promote plaque inflammation by secreting pro-inflammatory factors such as IL-1β. It was found that Mox has decreased chemotaxis and phagocytosis and high expression of antioxidant genes<sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup>. Mox macrophages were found to constitute up to 30% of macrophages in advanced atherosclerotic plaques<sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup>. Nrf2-mediated expression of a large number of antioxidant genes was found in Mox, indicating that Mox has an antioxidant effect. Mox also showed pro-inflammatory properties, and the expression of pro-inflammatory genes, such as IL-1β was elevated<sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup>. However, further research is needed to demonstrate Mox’s specific role in the chronic inflammatory process underlying atherosclerosis. Platelets are likewise thought to be involved in the atherosclerosis process, and platelet activation results in the release of chemokines stored in a-granules, which not only promote the adhesion of arterial endothelial cells and monocytes but also influence macrophage differentiation<sup>[<xref ref-type="bibr" rid="B25">25</xref>]</sup>. Notably, CXC chemokine ligand 4 (CXCL4), also known as platelet factor 4 (PF4), can activate M4 macrophages<sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup>. This protein inhibits CD163 expression, thereby reducing hemoglobin phagocytosis and processing by macrophages, and exhibits proatherogenic effects<sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup>. In contrast, macrophages exposed to hemoglobin-haptoglobin complexes (Hb-Hp) differentiate into M(Hb) and Mhem macrophages, which express relatively high levels of CD163 and heme oxygenase-1 (HO-1), promoting phagocytosis of aged or broken erythrocytes and iron recycling (discussed in detail in section “The role of macrophages in regulating lipid metabolism during atherogenesis”)<sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup> [<xref ref-type="fig" rid="fig1">Figure 1</xref>].</p>
        <fig id="fig1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Macrophage polarization in atherosclerotic plaques. During atherosclerotic plaque formation, endothelial activation recruits monocytes that infiltrate and differentiate into macrophages. Macrophages play dual roles, releasing both inflammatory and anti-inflammatory factors and participating in the clearance of ox-LDL and the formation of foam cells. Additionally, vascular smooth muscle cells contribute to macrophage formation through migration and differentiation. Macrophages undergo polarization into distinct phenotypes. LPS, ox-LDL, and pro-inflammatory factors promote macrophage M1 polarization, which plays a pro-inflammatory role by releasing IL-6, IL-1β, and TNF-α. IL-4 and IL-13 induce M2 macrophage polarization, and M2-type macrophages are further subdivided into M2a, M2b, M2c, and M2d, playing various roles, such as anti-inflammatory, pro-tissue repair, immunomodulation, facilitating the phagocytosis of apoptotic cells, and promoting angiogenesis. Macrophages induced Mox polarization by oxidized phospholipids and ox-LDL and exhibited antioxidant activity, low migration, and low phagocytic activity by synthesizing IL-1β, IL-10, and Nrf2. CXCL4 activates M4 macrophages that exhibit pro-inflammatory and pro-atherosclerotic development by increasing the expression of IL-6, MMPs, and TNF-α, and inhibiting CD163 expression. In response to hemoglobin, macrophages differentiate into M(Hb) and Mhem macrophages, which express higher levels of CD163 and HO-1, ABCA1/G1, HIF-α and VEGF-A. These macrophages promote cholesterol efflux, iron recycling, and angiogenesis, and contribute to the progression of atherosclerosis. Red arrows indicate upregulation/positive regulation (e.g., promoting pro-inflammatory cytokine expression and macrophage polarization toward pro-inflammatory phenotypes). Green arrows indicate downregulation/negative regulation (e.g., CXCL4-mediated inhibition of CD163 expression and anti-inflammatory/protective pathways). Created in BioRender. Fan, F. (2026) <uri xlink:href="https://BioRender.com/f63x996">https://BioRender.com/f63x996</uri>. ox-LDL: Oxidized low-density lipoprotein; LPS: lipopolysaccharide; IL: interleukin; TNF-α: tumor necrosis factor-alpha; TGF-β: transforming growth factor-beta; TLRs: Toll-like receptors; A2a receptor: adenosine A2 receptor; Nrf2: nuclear factor erythroid 2-related factor 2; CXCL4: CXC chemokine ligand 4; MMPs: matrix metalloproteinases; HO-1: heme oxygenase-1; ABCA1/G1: ATP-binding cassette transporter A1/G1; HIF-α: hypoxia-inducible factor-alpha; VEGF-A: vascular endothelial growth factor-A; CD163: cluster of differentiation 163; M(Hb): hemoglobin-associated macrophages.</p>
          </caption>
          <graphic xlink:href="mtod50190.fig.1.jpg"/>
        </fig>
        <p>The progression of atherosclerosis is primarily influenced by an imbalance in macrophage polarization, which leads to amplified pro-inflammatory effects and sustained inflammation<sup>[<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]</sup>. Damage to the endothelium and the subsequent infiltration and accumulation of macrophages are the early features of atherosclerosis development<sup>[<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]</sup>. Foam cell formation results from excessive lipid accumulation that exceeds the macrophage’s capacity for degradation and metabolism; if lipids are efficiently processed via pathways such as cholesterol efflux, foam cells do not form<sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup>. When anti-inflammatory macrophages are enriched, they stabilize plaques and promote plaque regression by synthesizing and releasing anti-inflammatory mediators and by facilitating collagen fiber synthesis<sup>[<xref ref-type="bibr" rid="B33">33</xref>]</sup>. Conversely, an increase in lipid deposition leads to an increase in the number of pro-inflammatory macrophages<sup>[<xref ref-type="bibr" rid="B34">34</xref>]</sup>. Pro-inflammatory macrophages maintain plaque inflammation by secreting pro-inflammatory factors such as IL-6, IL-1β, and tumor necrosis factor-alpha (TNF-α). When macrophages undergo ferroptosis within the atherosclerotic plaque, they become immunogenic, leading to the release of damage-associated molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), adenosine triphosphate (ATP), and mitochondrial DNA<sup>[<xref ref-type="bibr" rid="B35">35</xref>]</sup>. These DAMPs act as endogenous stress signals that engage pattern recognition receptors on neighboring macrophages and vascular cells, prompting the assembly and activation of inflammasomes, most notably the NLR family pyrin domain containing 3 (NLRP3) inflammasome. Upon activation, caspase-1 cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms, unleashing potent inflammatory mediators IL-1β and IL-18, while also triggering pyroptosis and further DAMPs release<sup>[<xref ref-type="bibr" rid="B36">36</xref>]</sup>. This sustained inflammatory feedback loop leads to increased recruitment of inflammatory cells, expansion of the necrotic core through accumulation of non-cleared dysregulated foam cells<sup>[<xref ref-type="bibr" rid="B37">37</xref>]</sup>. Additionally, matrix metalloproteinases (MMPs) secreted by pro-inflammatory macrophages degrade collagen fibers, increasing the risk of plaque rupture<sup>[<xref ref-type="bibr" rid="B38">38</xref>]</sup>. In advanced plaques, angiogenesis is a key characteristic. These fragile and leaky neovessels facilitate the release of red blood cells and promote the phagocytosis of erythrocytes by macrophages<sup>[<xref ref-type="bibr" rid="B39">39</xref>]</sup>. Hemoglobin-induced macrophage polarization toward M(Hb) and Mhem subtypes promotes intraplaque angiogenesis. CD163<sup>+</sup> macrophages increase Hb-Hp uptake and enhance the exocytosis of iron and lipids<sup>[<xref ref-type="bibr" rid="B40">40</xref>]</sup>. <italic>In vitro</italic> experiments indicate that this effect promotes atypical ferroptosis in macrophages, further contributing to plaque instability<sup>[<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]</sup>. In contrast to the previously held view that CD163<sup>+</sup> macrophages attenuate atherosclerosis, recent findings suggest that CD163<sup>+</sup> macrophages promote intraplaque angiogenesis, thereby increasing vascular permeability and inflammatory cell recruitment<sup>[<xref ref-type="bibr" rid="B43">43</xref>]</sup>. Advanced plaques instability is characterized by a necrotic core formed by apoptotic macrophages, the thinning of the fibrous cap caused by MMPs, and sustained inflammation. These factors significantly contribute to plaque rupture and acute cardiovascular events<sup>[<xref ref-type="bibr" rid="B31">31</xref>]</sup>. Both M1 and M2 macrophages coexist in plaques, with M1 macrophages concentrated in the rupture-prone shoulder region and M2 macrophages located in the fibrous cap region and near newly formed blood vessels<sup>[<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B44">44</xref>]</sup>.</p>
        <p>Throughout atherosclerosis development, polarized macrophages remain plastic, and the ratio of M1/M2 macrophages remains dynamic<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>. These macrophage subtypes can convert into each other and are influenced by cytokines in the plaque microenvironment. Specifically, M1 macrophages can undergo polarization toward M2 macrophages under the influence of IL-4, while M2 macrophages, when stimulated by lipopolysaccharide and IFN-γ, can also polarize into M1 macrophages<sup>[<xref ref-type="bibr" rid="B46">46</xref>]</sup>. These findings demonstrate that regulating the macrophage phenotype, such as promoting M1 macrophage polarization to the M2 phenotype, is a promising strategy for suppressing plaque inflammation and facilitating plaque regression.</p>
      </sec>
      <sec id="sec2-2">
        <title>The role of macrophages in regulating lipid metabolism during atherogenesis</title>
        <p>In early atherosclerosis, endothelial activation recruits monocytes, which differentiate into macrophages and initiate lipid uptake, processing, storage, and efflux at the lesion site<sup>[<xref ref-type="bibr" rid="B47">47</xref>]</sup>. Monocytes adhere, infiltrate, and differentiate into macrophages, initiating the clearance function<sup>[<xref ref-type="bibr" rid="B48">48</xref>]</sup>. The primary targets of macrophage clearance within the plaque include lipids and necrotic erythrocytes<sup>[<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>]</sup>. They maintain metabolic stability at the plaque site through phagocytosis, transformation, storage, and efflux<sup>[<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B51">51</xref>]</sup>.</p>
        <p>Macrophages express scavenger receptors, lectin-like ox-LDL receptor-1, and various other receptors on their surface, which enable the recognition and phagocytosis of lipids and reduce endothelial damage<sup>[<xref ref-type="bibr" rid="B52">52</xref>]</sup>. In the early stages of atherosclerosis, this effect is beneficial, as macrophages play a crucial role in removing harmful substances and preventing plaque formation, a process that is initially beneficial<sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup>. These macrophages utilize lysosomal acid lipase to transform ingested lipids into fatty acids and cholesterol<sup>[<xref ref-type="bibr" rid="B53">53</xref>]</sup>. Fatty acids are subsequently esterified into triglycerides in the endoplasmic reticulum, whereas cholesterol is esterified into cholesteryl esters<sup>[<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]</sup>. During fatty acid oxidation (FAO), these fatty acids serve as mitochondrial fuel to generate acetyl coenzyme A, which produces ATP<sup>[<xref ref-type="bibr" rid="B56">56</xref>]</sup>. This process begins with the activation of fatty acids in the cytoplasm, converting them into the more water-soluble acyl-coenzyme A (acyl-CoA)<sup>[<xref ref-type="bibr" rid="B57">57</xref>]</sup>. Following activation, the carnitine palmitoyl transferase system, facilitates the shuttling of acyl-CoA into the mitochondrial matrix. Once inside, it undergoes beta-oxidation (β-oxidation) to produce acetyl-CoA, which is ultimately metabolized to H<sub>2</sub>O and CO<sub>2</sub>, releasing substantial energy<sup>[<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]</sup>. This process runs in parallel with energy production from glucose oxidation, contributing to the energy requirements of macrophage activity and influencing macrophage function<sup>[<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>]</sup>. Studies have shown that M1 macrophages undergo aerobic glycolysis, whereas M2 macrophages engage in FAO<sup>[<xref ref-type="bibr" rid="B61">61</xref>]</sup>. Activation of the transcription factor signal transducer and activator of transcription 6 (STAT6) by IL-4 and IL-13 in M2 macrophages enhances CD36 expression, thereby increasing lipid uptake<sup>[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B62">62</xref>]</sup>. Furthermore, increases in both carnitine palmitoyl transferase expression and FAO have been observed. One study suggested that this upregulation contributed to the inhibition of atherosclerosis progression<sup>[<xref ref-type="bibr" rid="B63">63</xref>]</sup>. However, the necessity of FAO for M2 macrophage polarization is debated. Nomura <italic>et al.</italic> reported that inhibition of the FAO process did not impact IL-4-induced M2 macrophage polarization<sup>[<xref ref-type="bibr" rid="B64">64</xref>]</sup>. Additionally, emerging evidence suggests that dysregulated FAO in macrophages, particularly within atherosclerotic environments, can inadvertently promote NLRP3 inflammation through the release of DAMPs and subsequent activation of inflammasomes<sup>[<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B66">66</xref>]</sup>. As previously described, NLRP3 inflammasome activation promotes the release of IL-1β and IL-18, thereby enhancing the inflammatory circuit involving neighboring macrophages, endothelial cells, and smooth muscle cells. [<xref ref-type="fig" rid="fig2">Figure 2</xref>].</p>
        <fig id="fig2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Inflammatory and anti-inflammatory types of macrophages in the regulation of lipid metabolism. The macrophages’ surface SR-A, LOX-1, and CD36 recognize and phagocytose modified LDL, which is converted to fatty acids and cholesterol in the presence of LAL. Surplus cholesterol is partly translocated to extracellular apoA-I and HDL via ABCA1/G1, and the remaining cholesterol and free fatty acids are stored in lipid droplets. In pro-inflammatory macrophages, lipopolysaccharide activation of the TLR signaling pathway promotes SREBP1a transcription, which facilitates glucose uptake and <italic>de novo</italic> fatty acid synthesis, as well as the release of inflammatory factors via inflammatory vesicles. In anti-inflammatory macrophages, the IL-4/STAT6 signaling pathway is activated, promoting the expression of FAO-related genes. Free fatty acids are activated to acyl-CoA and shuttled into the mitochondria by CPT1 and CPT2, where they are oxidized in the presence of β-oxidation to form acetyl-CoA and ultimately ATP via the tricarboxylic acid cycle. In addition, CD36 expression is elevated, increasing lipid uptake. Created in BioRender. Fan, F. (2026) <uri xlink:href="https://BioRender.com/j64n485">https://BioRender.com/j64n485</uri>. SR-A: Scavenger receptors-A; LOX-1: lectin-like oxidized low-density lipoprotein receptor-1; LDL: low-density lipoprotein; LAL: lysosomal acid lipase; apoA-I: apolipoprotein A-I; HDL: high-density lipoprotein; ABCA1/G1: ATP-binding cassette transporter A1/G1; LPS: lipopolysaccharide; TLR: toll-like receptor; SREBP1a: sterol regulatory element binding transcription factor 1a; FAO: fatty acid oxidation; CPT: carnitine palmitoyl transferase; ATP: adenosine triphosphate; FA: fatty acids; CE: cholesterol; STAT6: signal transducer and activator of transcription 6; IL: interleukin; TCA: tricarboxylic acid cycle; CD36: cluster of differentiation 36; α-KG: alpha-ketoglutarate; acyl-CoA: acyl-coenzyme A; acetyl-CoA; acetyl-coenzyme A.</p>
          </caption>
          <graphic xlink:href="mtod50190.fig.2.jpg"/>
        </fig>
        <p>Triglycerides are predominantly stored within lipid droplets alongside other neutral lipids and surplus cholesterol esters<sup>[<xref ref-type="bibr" rid="B67">67</xref>]</sup>. Excess free cholesterol can be transported out of the cell and received by extracellular apolipoprotein A-I and high-density lipoprotein (HDL), facilitating its transfer via the ATP-binding cassette transporters ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1)<sup>[<xref ref-type="bibr" rid="B68">68</xref>]</sup>. Ox-LDL has been identified as a primary contributor to foam cell formation<sup>[<xref ref-type="bibr" rid="B69">69</xref>]</sup>. During atherosclerosis progression, elevated ox-LDL levels prompt increased scavenger receptor and LOX-1 expression in macrophages, while the expression of ABCA1/G1 is suppressed. However, other studies suggest that low-concentration ox-LDL may promote cholesterol efflux by upregulating ABCA1, while high-concentration ox-LDL inhibits ABCA1/G1 expression to exacerbate foam cell formation. This imbalance results in a significant lipid influx and increased phagocytosis by macrophages<sup>[<xref ref-type="bibr" rid="B52">52</xref>]</sup>. Lipid accumulation in macrophages results in their transformation into foam cells characterized by an abundance of lipid droplets<sup>[<xref ref-type="bibr" rid="B70">70</xref>]</sup>. These foam cells are prone to apoptosis, which causes inflammation and the formation of a necrotic core in atherosclerotic plaques<sup>[<xref ref-type="bibr" rid="B71">71</xref>,<xref ref-type="bibr" rid="B72">72</xref>]</sup>. This process is indicative of the fundamental alterations that occur in atherosclerosis. Acetylated LDL (ac-LDL) is another modified lipoprotein that is taken up by macrophages through scavenger receptors rather than the classical LDL receptor, thereby promoting unregulated cholesterol ester accumulation and foam cell formation<sup>[<xref ref-type="bibr" rid="B73">73</xref>]</sup>.</p>
        <p>Macrophages, in addition to their roles in phagocytosis, catabolism, lipid storage, and exocytosis, have also been found to play a role in lipid synthesis<sup>[<xref ref-type="bibr" rid="B59">59</xref>]</sup> [<xref ref-type="fig" rid="fig2">Figure 2</xref>]. Lipopolysaccharide produced by gram-negative bacteria was found to activate Toll-like receptor 4 on macrophage surfaces, enhancing glucose uptake and <italic>de novo</italic> synthesis of fatty acids<sup>[<xref ref-type="bibr" rid="B72">72</xref>,<xref ref-type="bibr" rid="B74">74</xref>,<xref ref-type="bibr" rid="B75">75</xref>]</sup>. At the same time, one of the classic DAMPs proteins, HMGB1, can also activate this process<sup>[<xref ref-type="bibr" rid="B35">35</xref>]</sup>. This activation is mediated through the TLR signaling pathway, which in turn triggers the transcription of sterol regulatory element-binding protein (SREBP) family proteins<sup>[<xref ref-type="bibr" rid="B76">76</xref>]</sup>. SREBPs are anchored to the endoplasmic reticulum facilitate LDL receptor expression, and enhance glucose transport, especially under reduced cholesterol conditions<sup>[<xref ref-type="bibr" rid="B77">77</xref>]</sup>. Acetyl-CoA generated during the tricarboxylic acid cycle fuels fatty acid synthesis with an energy supply from nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH)<sup>[<xref ref-type="bibr" rid="B78">78</xref>,<xref ref-type="bibr" rid="B79">79</xref>]</sup>. Research has shown that SREBP-1a deficiency leads to reduced macrophage lipid synthesis, and interactions between membrane phospholipid rafts with the actin cytoskeleton, thereby impairing phagocytosis<sup>[<xref ref-type="bibr" rid="B80">80</xref>]</sup>. Moreover, SREBP-1a is implicated not only in lipid synthesis but also in inflammasome activation, leading to IL-1β secretion and bolstering innate immunity<sup>[<xref ref-type="bibr" rid="B81">81</xref>]</sup>. This finding highlights the crucial role of lipid synthesis in supplying the necessary lipids and energy for membrane fusion during phagocytosis in macrophages, thereby enhancing their ability to combat pathogens. Conversely, during atherosclerosis progression, macrophages experience diminished lipid synthesis due to elevated cholesterol uptake and negative feedback regulation. This feedback involves the inhibition of SREBPs by the cholesterol metabolite 25-hydroxycholesterol<sup>[<xref ref-type="bibr" rid="B82">82</xref>]</sup>. Significantly, 25-hydroxycholesterol not only reduces lipid synthesis but also amplifies inflammation in lipid-rich macrophages, thereby promoting the progression of atherosclerosis<sup>[<xref ref-type="bibr" rid="B83">83</xref>]</sup>. In addition, recent studies have shown that 7-dehydrocholesterol (7-DHC), an intermediate in cholesterol synthesis, inhibits ferroptosis<sup>[<xref ref-type="bibr" rid="B84">84</xref>]</sup>. 7-DHC is converted to cholesterol in the presence of 7-DHC reductase, and macrophages are able to regulate 7-DHC reductase expression<sup>[<xref ref-type="bibr" rid="B85">85</xref>]</sup>. Since cholesterol accumulation is a crucial factor in macrophage foam cell formation and atherosclerosis, it is worth investigating whether macrophages regulate cholesterol synthesis and ferroptosis through 7-DHC in this context.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>MACROPHAGES AND FERROPTOSIS DURING ATHEROSCLEROSIS DEVELOPMENT</title>
      <p>The crucial role of macrophages in lipid and iron metabolism sets the stage for ferroptosis. Ferroptosis, identified as a novel form of non-caspase-dependent programmed cell death by Dixon <italic>et al.</italic> in 2012, has since been extensively investigated in various biological systems<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup>. Accumulating evidence strongly suggests that macrophage ferroptosis contributes to the development of atherosclerosis.</p>
      <sec id="sec3-1">
        <title>Overview of ferroptosis</title>
        <p>Ferroptosis is a process driven by iron-induced lipid peroxidation [<xref ref-type="fig" rid="fig3">Figure 3</xref>]. Macrophages generate significant amounts of Fe<sup>2+</sup> following the phagocytosis of erythrocytes and transferrin-bound iron, leading to cellular iron overload and the production of massive amounts of ROS via the Fenton reaction. Normally, macrophages produce moderate levels of ROS to combat pathogens. However, excessive ROS can damage lipids, proteins, and DNA<sup>[<xref ref-type="bibr" rid="B86">86</xref>]</sup>. First, free polyunsaturated fatty acids (PUFAs) undergo esterification facilitated by acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3). This process results in the attachment of PUFA tails to phospholipids (PL-PUFAs) and their doping of the cell membrane<sup>[<xref ref-type="bibr" rid="B87">87</xref>]</sup>. This process is thought to drive ferroptosis. PL-PUFAs become susceptible to ROS attack, forming lipid peroxides (PL-PUFA-OOH) that accumulate in the cell membrane, ultimately leading to destruction of the cell membrane structure and subsequent cell death, a hallmark of ferroptosis<sup>[<xref ref-type="bibr" rid="B88">88</xref>]</sup>. In addition to the Fe<sup>2+</sup>-mediated Fenton reaction, which generates ROS that promote lipid peroxidation, iron-independent enzymatic reactions such as lipoxygenases and cytochrome p450 oxidoreductase have also been found to promote the accumulation of lipid peroxides in cell membranes<sup>[<xref ref-type="bibr" rid="B89">89</xref>,<xref ref-type="bibr" rid="B90">90</xref>]</sup>.</p>
        <fig id="fig3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Mechanisms of ferroptosis inhibition in macrophages. PUFAs undergo esterification in the presence of ACSL4 and LPCAT3 to produce PL-PUFAs, which subsequently undergo peroxidation in the presence of ROS generated by the Fenton reaction or enzymatic reactions such as LOXs and POR to form PL-PUFA-OOH, which accumulates on the cell membrane and ultimately leads to ferroptosis. System xc- can exchange extracellular cystine and cellular glutamate for the synthesis of GSH, and GPX4 converts PL-PUFA-OOH to PL-PUFA-OH, while simultaneously oxidizing GSH to GSSG. Another ferroptosis mechanism is the FSP1/CoQ10/NAD(P)H axis, which reduces CoQ10 to CoQ10H2 using NADPH. Moreover, FSP1 exerts an anti-ferroptotic effect by regenerating vitamin E and promoting VKH2 production. Furthermore, GCH1 synthesizes GTP into BH4/BH2, which inhibits the oxidation of PL-PUFAs, and BH4 exerts an anti-lipid peroxidation effect by promoting the synthesis of CoQ10. In mitochondria, DHODH facilitates CoQ10H2 synthesis and inhibits ferroptosis in the inner mitochondrial membrane. MBOAT replaces PL-PUFAs with MUFAs incorporated into phospholipids to prevent PUFA oxidation. Additionally, iPLA2β inhibits ferroptosis by sheerly releasing oxidized PUFAs on phospholipids. Created in BioRender. Fan, F. (2026) <uri xlink:href="https://BioRender.com/o50j697">https://BioRender.com/o50j697</uri>. PUFAs: Polyunsaturated fatty acids; ACSL4: acyl-CoA synthetase long-chain family member 4; LPCAT3: lysophosphatidylcholine acyltransferase 3; PL-PUFA: phospholipid containing polyunsaturated fatty acid chain; ROS: reactive oxygen species; LOXs: lipoxygenases; POR: p450 oxidoreductase; PL-PUFA-OOH: phospholipids with peroxidized polyunsaturated fatty acyl tail; GSH: glutathione; GPX4: glutathione peroxidase 4; GSSG: glutathione disulfide; Glu: glutamate; Cys: Cysteine; FSP1: ferroptosis suppressor protein 1; VKH<sub>2</sub>: vitamin K hydroquinone; GCH1: GTP cyclohydrolase 1; GTP: guanosine triphosphate; BH4: tetrahydrobiopterin; BH2: dihydrobiopterin; DHODH: dihydroorotate dehydrogenase; MBOAT: membrane-bound O-acyltransferase; MUFA: monounsaturated fatty acids; iPLA2β: calcium-independent phospholipase A2 beta; LIP: labile iron pool; PL-MUFA: phospholipid containing monounsaturated fatty acid chain; System xc-: cystine/glutamate antiporter; CoQ<sub>10</sub>: coenzyme Q10; CoQ<sub>10</sub>H<sub>2</sub>: ubiquinol (reduced coenzyme Q10); NADPH: nicotinamide adenine dinucleotide phosphate (reduced form); NADP<sup>+</sup>: nicotinamide adenine dinucleotide phosphate (oxidized form); PL-PUFA-OH: phospholipid with hydroxylated polyunsaturated fatty acyl tail; PUFA-CoA: polyunsaturated fatty acyl-coenzyme A.</p>
          </caption>
          <graphic xlink:href="mtod50190.fig.3.jpg"/>
        </fig>
        <p>Cells generally counteract ferroptosis through mechanisms, such as the cystine/glutamate antiporter (System xc-)/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis, a crucial component [<xref ref-type="fig" rid="fig3">Figure 3</xref>]. System xc- consists of two subunits, solute carrier family 7 member 11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2), exchanging extracellular cystine with intracellular glutamate at a 1:1 ratio<sup>[<xref ref-type="bibr" rid="B91">91</xref>,<xref ref-type="bibr" rid="B92">92</xref>]</sup>. GSH is synthesized from cystine with relevant enzymes. Subsequently, GPX4 oxidizes GSH to oxidize glutathione (GSSG) while reducing PL-PUFA-OOH to the corresponding alcohol (PL-PUFA-OH)<sup>[<xref ref-type="bibr" rid="B93">93</xref>]</sup>. However, in certain tumor cells, sensitivity to GPX4 inhibitors is not observed due to an anti-ferroptotic mechanism that runs in parallel with the System xc-/GSH/GPX4 axis, known as ferroptosis suppressor protein 1 (FSP1)/ubiquinone (CoQ<sub>10</sub>)/NAD(P)H axis [<xref ref-type="fig" rid="fig3">Figure 3</xref>]. FSP1, also known as apoptosis-inducing factor mitochondria-associated 2 (AIFM2), plays a central role in this axis. FSP1 reduces CoQ<sub>10</sub> to ubiquinol (CoQ<sub>10</sub>H<sub>2</sub>) in the presence of NADPH, which is a lipophilic antioxidant that captures lipid peroxides and prevents their accumulation<sup>[<xref ref-type="bibr" rid="B94">94</xref>]</sup>. In addition, FSP1 exerts anti-ferroptosis effects through CoQ<sub>10</sub> or direct promotion of a-tocopherol (vitamin E) regeneration<sup>[<xref ref-type="bibr" rid="B95">95</xref>]</sup>. Furthermore, studies have reported that vitamin K also has an anti-ferroptosis effect, while FSP1 can reduce vitamin K to vitamin K hydroquinone (VKH<sub>2</sub>) to attenuate lipid peroxidation<sup>[<xref ref-type="bibr" rid="B96">96</xref>]</sup>.</p>
        <p>Moreover, additional independent mechanisms of resistance to ferroptosis are gradually being uncovered [<xref ref-type="fig" rid="fig3">Figure 3</xref>]. For example, Kraft <italic>et al.</italic> reported that the GTP cyclohydrolase 1 (GCH1)/tetrahydrobiopterin (BH<sub>4</sub>) axis inhibits ferroptosis through lipid remodeling<sup>[<xref ref-type="bibr" rid="B97">97</xref>]</sup>. BH<sub>4</sub> and dihydrobiopterin (BH<sub>2</sub>), synthesized by GCH1, protect the phospholipid PUFA tail from oxidation, thereby preventing cell membrane disruption. BH<sub>4</sub> has also been shown to promote CoQ<sub>10</sub> synthesis by facilitating the conversion of phenylalanine to tyrosine, thereby exerting an anti-lipid-peroxidation effect<sup>[<xref ref-type="bibr" rid="B97">97</xref>]</sup>. Dihydroorotate dehydrogenase (DHODH), which functions similarly to FSP1, promotes ubiquitin production in mitochondria and inhibits ferroptosis in the inner mitochondrial membrane<sup>[<xref ref-type="bibr" rid="B98">98</xref>]</sup>. Membrane-bound O-acyltransferase 1 and 2 (MBOAT1/2), which are regulated by sex hormones, perform ferroptosis surveillance functions independently of GPX4 and FSP1<sup>[<xref ref-type="bibr" rid="B99">99</xref>]</sup>. MBOAT2 transfers monounsaturated fatty acids (MUFAs) to phospholipid precursors and synthesizes MUFA-rich phospholipids to replace PL-PUFAs in preventing PUFA oxidation and effectively inhibiting cell damage from ferroptosis inducers<sup>[<xref ref-type="bibr" rid="B99">99</xref>]</sup>. Furthermore, calcium-independent phospholipase A2 beta (iPLA2β) was found to be induced by ROS and to cleave and release oxidized PUFAs from phospholipids, further inhibiting ferroptosis<sup>[<xref ref-type="bibr" rid="B100">100</xref>]</sup>.</p>
      </sec>
      <sec id="sec3-2">
        <title>The role of macrophages in regulating iron metabolism</title>
        <p>Macrophages are central to systemic iron recycling. They phagocytose senescent erythrocytes, process hemoglobin, import transferrin-bound iron, and either store excess iron in ferritin or export it via ferroportin. Macrophages recognize and phagocytose senescent erythrocytes and break down hemoglobin in the presence of HO-1 to generate Fe<sup>2+[<xref ref-type="bibr" rid="B101">101</xref>]</sup>. Another source of iron in macrophages is Fe<sup>3+</sup> from the circulation. Assisted by transferrin (TF), the Fe<sup>3+</sup>-TF conjugate is recognized by transferrin receptor 1 (TFR1) on the macrophage surface and enters the cytoplasm via endocytosis<sup>[<xref ref-type="bibr" rid="B102">102</xref>,<xref ref-type="bibr" rid="B103">103</xref>]</sup>. The six-segment transmembrane epithelial antigen of prostate 3 (STEAP3), expressed on endosomes, plays a crucial role in reducing <InlineParagraph>Fe<sup>3+</sup></InlineParagraph> to <InlineParagraph>Fe<sup>2+</sup></InlineParagraph> and is translocated to the labile iron pool via divalent metal transporter 1 (DMT1)<sup>[<xref ref-type="bibr" rid="B104">104</xref>]</sup>. To maintain iron homeostasis, excess Fe<sup>2+</sup> is expelled from macrophages via ferroportin, the only known transporter facilitating Fe<sup>2+</sup> efflux<sup>[<xref ref-type="bibr" rid="B105">105</xref>]</sup>. Ferroportin expression is controlled by hepcidin, which is synthesized in the liver<sup>[<xref ref-type="bibr" rid="B106">106</xref>,<xref ref-type="bibr" rid="B107">107</xref>]</sup>. The remaining Fe<sup>2+</sup> forms a secure storage reservoir by binding to ferritin, creating a non-toxic metalloprotein complex<sup>[<xref ref-type="bibr" rid="B108">108</xref>]</sup>. During episodes of iron deficiency, nuclear receptor coactivator 4 binds to ferritin, triggering autophagosome formation. These autophagosomes merge with lysosomes, leading to the catabolism of ferritin and the subsequent release of Fe<sup>2+</sup> to maintain optimal iron levels<sup>[<xref ref-type="bibr" rid="B109">109</xref>,<xref ref-type="bibr" rid="B110">110</xref>]</sup>. However, intracellular iron homeostasis can be disrupted for various reasons, leading to iron overload within macrophages. Excessive Fe<sup>2+</sup> induces the Fenton reaction, producing significant amounts of ROS and potentially causing extensive cellular damage<sup>[<xref ref-type="bibr" rid="B111">111</xref>]</sup> [<xref ref-type="fig" rid="fig4">Figure 4</xref>].</p>
		<fig id="fig4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Origin and metabolic pathways of iron in macrophages. Two pathways contribute to the source of iron in macrophages. One of them is the recognition and phagocytosis of senescent erythrocytes or Hb-Hp formed after the rupture of erythrocytes via receptors such as CD163 on the surface of macrophages, which are catabolized by HO-1 to produce Fe<sup>2+</sup>, which is translocated to the LIP in the presence of DMT1. Another source is circulating Fe<sup>3+</sup>. Assisted by TF, the Fe<sup>3+</sup>-TF conjugate is recognized by TFR1 on the macrophage surface, reduces Fe<sup>3+</sup> to Fe<sup>2+</sup> via STEAP3, and finally translocates to the LIP via DMT1. Excess Fe<sup>2+</sup> is excreted from macrophages via Ferroportin, which is controlled by hepcidin synthesized by the liver. Extra Fe<sup>2+</sup> is bound to ferritin and stored. Under iron deficiency conditions, NCOA4 binds to ferritin and initiates the fusion of autophagosomes with lysosomes, leading to ferritin catabolism and subsequent release of Fe<sup>2+</sup>. Iron overload forms excess Fe<sup>2+,</sup> inducing a Fenton reaction that produces large amounts of ROS. Created in BioRender. Fan, F. (2026) <uri xlink:href="https://BioRender.com/r45f260">https://BioRender.com/r45f260</uri>. Hb-Hp: Hemoglobin-haptoglobin; HO-1: heme oxygenase-1; LIP: labile iron pool; DMT1: divalent metal transporter 1; TF: transferrin; TFR1: transferrin receptor 1; STEAP3: six-segment transmembrane epithelial antigen of prostate 3; FPN: ferroportin; NCOA4: nuclear receptor coactivator 4; ROS: reactive oxygen species; CD163: cluster of differentiation 163; RBC: red blood cell.</p>
          </caption>
          <graphic xlink:href="mtod50190.fig.4.jpg"/>
        </fig>
        <p>Research indicates that iron overload can contribute to vascular endothelial disorders and exacerbate atherosclerosis<sup>[<xref ref-type="bibr" rid="B92">92</xref>,<xref ref-type="bibr" rid="B112">112</xref>]</sup>. Hereditary hemochromatosis, characterized by systemic iron overload due to abnormally increased iron absorption, is associated with an increased risk of CVD<sup>[<xref ref-type="bibr" rid="B113">113</xref>,<xref ref-type="bibr" rid="B114">114</xref>]</sup>. Similarly, mouse models with Ferroportin mutations exhibited elevated levels of non-transferrin-bound iron and displayed more severe atherosclerosis<sup>[<xref ref-type="bibr" rid="B114">114</xref>]</sup>. In addition, iron overload has been shown to promote M1 polarization in atherosclerotic macrophages and maintain inflammatory levels. This phenomenon might be attributed to iron-enhanced macrophage glycolysis<sup>[<xref ref-type="bibr" rid="B115">115</xref>]</sup>. In hemorrhagic areas of atherosclerotic plaques, hemoglobin-derived iron is a key factor in macrophage differentiation, inflammation, and lipid metabolism<sup>[<xref ref-type="bibr" rid="B116">116</xref>]</sup>. Aging and ruptured erythrocytes release substantial hemoglobin, which forms Hb-Hp with haptoglobin, as mentioned previously<sup>[<xref ref-type="bibr" rid="B117">117</xref>]</sup>. Through CD163, macrophages recognize and phagocytose Hb-Hp, further implicating iron in the intricate processes associated with atherosclerosis<sup>[<xref ref-type="bibr" rid="B118">118</xref>,<xref ref-type="bibr" rid="B119">119</xref>]</sup>. This action drives macrophage polarization into subtypes distinct from M1 and M2: hemoglobin-associated macrophages M(Hb) and Mhem, characterized by high expression of Ferroportin, resulting in lower intracellular iron and ROS levels. Moreover, increased expression of ABCA1/G1 promotes the efflux of intracellular cholesterol<sup>[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B23">23</xref>]</sup>. These distinct macrophage subtypes, characterized by diminished iron content and reduced lipid accumulation, replace foam cells and appear to attenuate atherosclerosis progression. However, further studies contradict this view. CD163<sup>+</sup> macrophages induce hypoxia-inducible factor 1-alpha (HIF-1α) and vascular endothelial growth factor A (VEGF-A) expression, leading to increased plaque microvessel formation, enhanced vascular permeability, and recruitment of additional inflammatory cells<sup>[<xref ref-type="bibr" rid="B43">43</xref>]</sup>. Similarly, oxidation of hemoglobin to ferrylHb in atherosclerotic plaques promotes the polarization of the macrophage pro-inflammatory phenotype, thereby contributing to the development of atherosclerosis<sup>[<xref ref-type="bibr" rid="B120">120</xref>]</sup>. Furthermore, hemoglobin deposition due to intraplaque hemorrhage induced macrophage ferroptosis and expression of MMP2/9, which increased plaque instability. This effect is reversible by Ferrostatin-1 (Fer-1), a ferroptosis inhibitor<sup>[<xref ref-type="bibr" rid="B42">42</xref>]</sup>. These results suggest that M(Hb) and Mhem with low levels of iron may not have a reduced degree of ferroptosis.</p>
        <p>In conclusion, the role of macrophages in maintaining systemic iron homeostasis is indisputable. Additionally, iron levels reciprocally influence macrophage function. During atherosclerosis progression, they play a pivotal role in hemoglobin- or transferrin-bound iron uptake, generating Fe<sup>2+</sup> that can either be excreted extracellularly via Ferroportin or stored as ferritin-bound iron. However, excessive iron induces macrophage ferroptosis, leading to plaque destabilization in atherosclerosis.</p>
      </sec>
      <sec id="sec3-3">
        <title>Macrophage ferroptosis in atherosclerosis and its regulators</title>
        <p>Because macrophages simultaneously control iron trafficking and lipid handling, they are especially vulnerable to ferroptosis; in turn, ferroptosis further promotes M1 polarization, lipid retention, and inflammatory amplification, creating a self-reinforcing loop in plaques<sup>[<xref ref-type="bibr" rid="B121">121</xref>]</sup>. Studies have shown that ferroptosis affects macrophage polarization. For example, ACSL4 was reported to promote macrophage ferroptosis and M1 polarization and regulate nasopharyngeal carcinoma tumorigenesis<sup>[<xref ref-type="bibr" rid="B122">122</xref>]</sup>. Microglia ferroptosis promotes M1 polarization in spinal cord injury<sup>[<xref ref-type="bibr" rid="B123">123</xref>]</sup>. Conversely, the inhibition of ferroptosis promotes macrophage M2 polarization<sup>[<xref ref-type="bibr" rid="B124">124</xref>,<xref ref-type="bibr" rid="B125">125</xref>]</sup>. In atherosclerosis, there is increasing evidence that macrophages undergo ferroptosis and promote plaque progression. Specifically, disrupted iron metabolism in macrophages leads to iron overload, triggering excessive ROS production and sustaining the M1 phenotype, thereby resulting in a persistent inflammatory state in atherosclerotic plaques<sup>[<xref ref-type="bibr" rid="B126">126</xref>]</sup>. In addition, the absorption of excess ox-LDL by macrophages contributes to foam cell formation and increases ferroptosis susceptibility<sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup>. The accumulation of foam cells forms a necrotic core, thus increasing plaque instability<sup>[<xref ref-type="bibr" rid="B127">127</xref>]</sup>. A previous study reported that macrophage iron retention enhances ox-LDL uptake and activates the Toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kB) pathway. Concurrently, it inhibits liver X receptor alpha (LXRα)- and ABCA1/G1-dependent cholesterol efflux, exacerbating cellular foaminess<sup>[<xref ref-type="bibr" rid="B128">128</xref>]</sup>. This evidence suggests a vicious cycle in atherosclerotic macrophages, in which iron and lipids continue to accumulate and interact, exacerbating metabolic imbalance.</p>
        <p>Emerging evidence suggests that macrophage ferroptosis may also promote plaque calcification through extracellular vesicle release, extracellular matrix (ECM) remodeling, and iron-driven oxidative stress, although direct <italic>in vivo</italic> causal evidence remains limited. First, ferroptotic macrophages can generate death remnants, analogous to apoptotic bodies, that serve as nucleation sites for calcium-phosphate crystal formation, thereby promoting microcalcification and potentially accelerating plaque destabilization<sup>[<xref ref-type="bibr" rid="B129">129</xref>]</sup>. Second, evidence suggests that the death of macrophages, including apoptosis, pyroptosis, necrosis, and ferroptosis, generates extracellular vesicles (EVs), which serve as the starting point for microcalcification nodules<sup>[<xref ref-type="bibr" rid="B129">129</xref>]</sup>. EVs released when macrophages undergo ferroptosis not only contain factors such as Runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and osteocalcin, which promote bone differentiation, but also trigger the release of iron-containing EVs. Upon uptake by surrounding cells, these iron-laden EVs increase ROS/lipid peroxidation, stress signals that have been demonstrated to promote osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs)<sup>[<xref ref-type="bibr" rid="B130">130</xref>,<xref ref-type="bibr" rid="B131">131</xref>]</sup>. The iron and oxidized lipids released from necrotic cores or potential ferroptotic remnants of macrophages within plaques can induce local oxidative stress and inflammation, disrupting the integrity of the surrounding ECM<sup>[<xref ref-type="bibr" rid="B132">132</xref>]</sup>. This exposure of phosphate-binding sites subsequently promotes the deposition of calcium salts. Current evidence supports the link between ferroptosis and plaque calcification through multiple pathways, including EV secretion, ECM remodeling, pro-inflammatory and pro-oxidative environments, and VSMC osteogenic transdifferentiation. However, no study yet has demonstrated a complete <italic>in vivo</italic> causal chain from macrophage ferroptosis to terminal plaque calcification, underscoring the need for systematic validation.</p>
        <p>The connection between ferroptosis and other macrophage types in atherosclerosis is not well understood, and further research is needed to explore the sensitivity of Mox, M4, M(Hb), and Mhem cells to ferroptosis and whether ferroptosis influences their polarization. These subsets differ in their antioxidant/heme-handling programs, lipid uptake, and proteolytic profiles, and may therefore exhibit distinct vulnerabilities to iron-dependent lipid peroxidation. This has important implications for the release of DAMPs and inflammasome-mediated inflammation. Future work should therefore clarify which phenotypes are more prone to ferroptotic versus ferroptosis-resistant states, and whether ferroptosis acts upstream to skew polarization or downstream as a consequence of metabolism- and iron-handling-specific processes in subsets. Elucidating these relationships could reveal phenotype-specific therapeutic targets to limit DAMP-driven inflammation and stabilize vulnerable plaques.</p>
        <p>Ferroptosis is a form of cell death characterized by an imbalance between oxidation and antioxidant defenses, intricately regulated by various mechanisms. Various ferroptosis regulators influence the atherosclerotic process by modulating macrophage ferroptosis. Among these, the transcription factor Nrf2 strongly contributes to the suppression of oxidative stress caused by ROS<sup>[<xref ref-type="bibr" rid="B133">133</xref>]</sup>. Its classical activation pathway is the Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 pathway. Under low intracellular ROS conditions, Keap1 can bind, immobilize, and sequester Nrf2 in the cytoplasm. Moreover, Keap1 facilitates the ubiquitination of Nrf2 via the E3 ubiquitin ligase, thereby inhibiting its activation<sup>[<xref ref-type="bibr" rid="B134">134</xref>]</sup>. Conversely, when ROS levels are elevated, cysteine residues in specific structural domains in Keap1 are oxidized, altering Keap1 conformation and the release of Nrf2<sup>[<xref ref-type="bibr" rid="B134">134</xref>]</sup>. The nuclear translocation of Nrf2 promotes the transcription of antioxidant genes, including superoxide dismutase and catalase, promoting the metabolism of ROS. It also includes GPX4, GSH, and other inhibitors of ferroptosis, and HO-1, which promotes heme catabolism<sup>[<xref ref-type="bibr" rid="B135">135</xref>,<xref ref-type="bibr" rid="B136">136</xref>]</sup>. Studies on atherosclerosis have shown that Nrf2-deficient macrophages exhibit elevated inflammation, altered iron homeostasis, and increased transcription of cell-damage-related genes<sup>[<xref ref-type="bibr" rid="B137">137</xref>]</sup>. Targeting the Keap1/Nrf2 pathway upregulated macrophage GPX4 and system xc- levels, thereby inhibiting ferroptosis to attenuate atherosclerosis<sup>[<xref ref-type="bibr" rid="B138">138</xref>]</sup>.</p>
        <p>Another mechanism regulating ferroptosis in atherosclerotic macrophages is the hepcidin/Ferroportin pathway<sup>[<xref ref-type="bibr" rid="B139">139</xref>,<xref ref-type="bibr" rid="B140">140</xref>]</sup>. Hepcidin, which is synthesized by the liver, is the principal regulator of circulating iron levels and the maintenance of iron homeostasis<sup>[<xref ref-type="bibr" rid="B141">141</xref>]</sup>. When circulating iron levels are elevated, hepcidin is synthesized by the liver to regulate Ferroportin on the surface of enterocytes, macrophages, and other cells, decreasing cellular iron efflux to lower circulating iron levels<sup>[<xref ref-type="bibr" rid="B142">142</xref>,<xref ref-type="bibr" rid="B143">143</xref>]</sup>. The contribution of iron to atherosclerosis, a subject of debate for decades (referred to as the iron hypothesis), has garnered recent support<sup>[<xref ref-type="bibr" rid="B144">144</xref>]</sup>. Extensive evidence has identified hepcidin as a risk factor for atherosclerosis<sup>[<xref ref-type="bibr" rid="B145">145</xref>-<xref ref-type="bibr" rid="B147">147</xref>]</sup>. Moreover, intracellular iron homeostasis in macrophages is directly regulated by the hepcidin/Ferroportin pathway. Activation of the hepcidin/Ferroportin pathway results in an increase in intracellular iron levels within macrophages. This elevation in iron levels contributes to the maintenance of the M1 phenotype, promotes inflammation, induces ferroptosis, and facilitates atherosclerosis progression<sup>[<xref ref-type="bibr" rid="B140">140</xref>,<xref ref-type="bibr" rid="B148">148</xref>,<xref ref-type="bibr" rid="B149">149</xref>]</sup>. Furthermore, the inhibition of hepcidin increases macrophage cholesterol efflux, attenuating atherosclerosis<sup>[<xref ref-type="bibr" rid="B150">150</xref>]</sup>. Notably, <InlineParagraph>Xiao <italic>et al.</italic></InlineParagraph> found that atherosclerotic macrophages exposed to ox-LDL promote hepcidin autocrine via the TLR4/NF-kB pathway and contributed to ox-LDL uptake and foam cell formation<sup>[<xref ref-type="bibr" rid="B128">128</xref>]</sup>.</p>
        <p>Tumor suppressor p53 (p53), a crucial transcription factor, regulates various cellular functions, including cell cycle, senescence, death, and so on<sup>[<xref ref-type="bibr" rid="B151">151</xref>]</sup>. In ferroptosis, the regulatory role of p53 is bidirectional, complex, and tissue-specific, influenced by the extent of cellular damage and ROS levels<sup>[<xref ref-type="bibr" rid="B152">152</xref>]</sup>. On one side, p53 directly inhibits SLC7A11 function through acetylation, promoting ferroptosis by inhibiting GSH synthesis and GPX4 activity<sup>[<xref ref-type="bibr" rid="B153">153</xref>]</sup>. Moreover, p53 can transcriptionally activate spermidine/spermine N1-acetyltransferase 1 (SAT1) and promote lipid peroxidation through its downstream arachidonate 15-lipoxygenase (ALOX5), thereby inducing ferroptosis<sup>[<xref ref-type="bibr" rid="B154">154</xref>]</sup>. On the other hand, p53 also regulates cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21), which promotes the expression of GPX4 and exerts anti-ferroptosis effects<sup>[<xref ref-type="bibr" rid="B155">155</xref>]</sup>. Furthermore, p53 facilitates oxidized PUFA tail separation from phospholipid to protect cell membranes from ferroptosis attack by regulating iPLA2β expression<sup>[<xref ref-type="bibr" rid="B100">100</xref>]</sup>.</p>
        <p>In atherosclerosis, p53 has a bidirectional role, that may vary with disease stage. In advanced atherosclerotic plaques, elevated p53 expression inhibits vascular smooth muscle cell apoptosis while promoting macrophage apoptosis, and inhibiting atherosclerosis progression<sup>[<xref ref-type="bibr" rid="B156">156</xref>]</sup>. In contrast, increased ROS from iron overload induced M1 polarization in macrophage via p53 acetylation. Meanwhile, ox-LDL promotes macrophage p53-dependent apoptosis<sup>[<xref ref-type="bibr" rid="B157">157</xref>,<xref ref-type="bibr" rid="B158">158</xref>]</sup>, likely exacerbating atherosclerosis. This complex, bidirectional nature of p53 in atherosclerosis and its impact on macrophage ferroptosis warrant further research for a comprehensive understanding.</p>
        <p>Several regulators also play important roles in ferroptosis, including the Hippo/Yes-associated protein (YAP) signaling pathway. This pathway directly enhances the transcription of ACSL4 and TFR1, thereby facilitating cellular ferroptosis<sup>[<xref ref-type="bibr" rid="B159">159</xref>]</sup>. Additionally, hypoxia-inducible factors (HIFs), a group of proteins stably expressed under low-oxygen conditions, regulate the expression of metabolism-related genes. Research indicates that HIF-1α induced macrophage ferroptosis promotes atherosclerosis<sup>[<xref ref-type="bibr" rid="B160">160</xref>]</sup>. Similarly, HIF-2α induces lipid droplet-associated protein expression in hypoxic conditions, increasing polyunsaturated lipid accumulation<sup>[<xref ref-type="bibr" rid="B161">161</xref>]</sup>. This finding implies a potential role for HIF-2α in promoting macrophage foam cell formation and ferroptosis under hypoxic conditions, although further investigation is needed. In addition, the AMP-activated protein kinase (AMPK) pathway can prevent ox-LDL-induced ferroptosis in macrophages, mitigating the atherosclerotic process<sup>[<xref ref-type="bibr" rid="B162">162</xref>]</sup>. This protective mechanism may stem from the role of AMPK in the phosphorylation of acetyl coenzyme A carboxylase and the synthesis of PUFAs under energy stress or glucose deficiency<sup>[<xref ref-type="bibr" rid="B163">163</xref>]</sup>.</p>
      </sec>
    </sec>
    <sec id="sec4">
      <title>THERAPEUTIC OPTIONS FOR ATTENUATING ATHEROSCLEROSIS BY INHIBITING FERROPTOSIS IN MACROPHAGES</title>
      <p>Because macrophage ferroptosis sits at the intersection of iron overload, lipid peroxidation, and plaque inflammation, its pharmacological inhibition is a rational therapeutic strategy for atherosclerosis. However, such research is currently limited. In recent years, numerous studies have reported the use of drugs for treating various systemic diseases by inhibiting macrophage ferroptosis, including various compounds, natural plant extracts, and other agents. The potential value of such medications in treating atherosclerosis is also high. It is summarized as follows to provide new ideas for the treatment of atherosclerosis [<xref ref-type="table" rid="t1">Table 1</xref>].</p>
      <table-wrap id="t1">
        <label>Table 1</label>
        <caption>
          <p>The potential medicines inhibiting ferroptosis in macrophages</p>
        </caption>
        <table frame="hsides" rules="groups">
  <tbody>
    <tr>
      <td>
        <bold>Type</bold>
      </td>
      <td>
        <bold>Medicine</bold>
      </td>
      <td>
        <bold>Target</bold>
      </td>
      <td>
        <bold>Diseases</bold>
      </td>
      <td>
        <bold>Reference</bold>
      </td>
    </tr>
    <tr>
      <td rowspan="11">Organic compounds</td>
      <td>Metformin</td>
      <td>AMPK/ERK</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B162">162</xref>]</td>
    </tr>
    <tr>
      <td rowspan="3">Dexmedetomidine</td>
      <td>Keap1/Nrf2/HO-1</td>
      <td>Ischemic-reperfusion injury</td>
      <td>[<xref ref-type="bibr" rid="B165">165</xref>]</td>
    </tr>
    <tr>
      <td>PPARγ/STAT3</td>
      <td>Liver ischemia and reperfusion injury</td>
      <td>[<xref ref-type="bibr" rid="B166">166</xref>]</td>
    </tr>
    <tr>
      <td>Nrf2/GPX4</td>
      <td>Hepatic ischemia-reperfusion injury</td>
      <td>[<xref ref-type="bibr" rid="B167">167</xref>]</td>
    </tr>
    <tr>
      <td rowspan="3">Itaconate</td>
      <td>Nrf2 via alkylation of Keap1</td>
      <td>Inflammatory diseases</td>
      <td>[<xref ref-type="bibr" rid="B168">168</xref>]</td>
    </tr>
    <tr>
      <td>Nrf2</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B169">169</xref>]</td>
    </tr>
    <tr>
      <td>Nrf2</td>
      <td>Acute lung injury</td>
      <td>[<xref ref-type="bibr" rid="B170">170</xref>]</td>
    </tr>
    <tr>
      <td>Uridine</td>
      <td>Nrf2 Activation and ACSL4 Inhibition</td>
      <td>Induced acute lung injury</td>
      <td>[<xref ref-type="bibr" rid="B171">171</xref>]</td>
    </tr>
    <tr>
      <td>Ferritin-1 and iron chelators</td>
      <td>GPX4</td>
      <td>Mycobacterium tuberculosis</td>
      <td>[<xref ref-type="bibr" rid="B172">172</xref>]</td>
    </tr>
    <tr>
      <td>Thymosin β4</td>
      <td>GPX4</td>
      <td>Non-alcoholic fatty liver</td>
      <td>[<xref ref-type="bibr" rid="B173">173</xref>,<xref ref-type="bibr" rid="B174">174</xref>]</td>
    </tr>
    <tr>
      <td>Semaphorin 5A</td>
      <td>PI3K-AKT-mTOR</td>
      <td>Rheumatoid arthritis</td>
      <td>[<xref ref-type="bibr" rid="B175">175</xref>]</td>
    </tr>
    <tr>
      <td rowspan="12">Natural botanical extracts and derivatives</td>
      <td>Puerarin</td>
      <td>ACSL4, PTGS, ALOX15, GPX4</td>
      <td>Macrophage inflammation</td>
      <td>[<xref ref-type="bibr" rid="B177">177</xref>]</td>
    </tr>
    <tr>
      <td rowspan="2">Micheliolide</td>
      <td>Mtdh/BMP/MAPK</td>
      <td>Renal fibrosis</td>
      <td>[<xref ref-type="bibr" rid="B178">178</xref>]</td>
    </tr>
    <tr>
      <td>Keap1/Nrf2</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B138">138</xref>]</td>
    </tr>
    <tr>
      <td>Sulforaphane</td>
      <td>Nrf2</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B180">180</xref>]</td>
    </tr>
    <tr>
      <td>Naringenin</td>
      <td>Nrf2/System xc-/GPX4</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B181">181</xref>-<xref ref-type="bibr" rid="B185">185</xref>]</td>
    </tr>
    <tr>
      <td rowspan="2">Quercetin</td>
      <td rowspan="2">GPX4, SLC7A11</td>
      <td>Neutrophilic airway inflammation</td>
      <td>[<xref ref-type="bibr" rid="B187">187</xref>]</td>
    </tr>
    <tr>
      <td>Acute kidney injury</td>
      <td>[<xref ref-type="bibr" rid="B188">188</xref>]</td>
    </tr>
    <tr>
      <td>CeCH NPs</td>
      <td>GPX4</td>
      <td>Sepsis-induced cardiac injury</td>
      <td>[<xref ref-type="bibr" rid="B189">189</xref>]</td>
    </tr>
    <tr>
      <td>β-Caryophyllene</td>
      <td>CB2R</td>
      <td>Ulcerative colitis</td>
      <td>[<xref ref-type="bibr" rid="B190">190</xref>]</td>
    </tr>
    <tr>
      <td>Baicalein</td>
      <td>HMOX1, SLC40A1, FTH1</td>
      <td>Ovarian endometriosis</td>
      <td>[<xref ref-type="bibr" rid="B191">191</xref>]</td>
    </tr>
    <tr>
      <td>Liensinine</td>
      <td>Ferritin autophagy</td>
      <td>Acute liver injury</td>
      <td>[<xref ref-type="bibr" rid="B192">192</xref>,<xref ref-type="bibr" rid="B193">193</xref>]</td>
    </tr>
    <tr>
      <td>JFNE and JFNE-C</td>
      <td>STAT3/p53/SLC7A11</td>
      <td>Inflammatory diseases</td>
      <td>[<xref ref-type="bibr" rid="B194">194</xref>]</td>
    </tr>
    <tr>
      <td rowspan="4">Compound formulations</td>
      <td>Maijitong granule</td>
      <td>STAT6/DMT1 and STAT6/SOCS1/p53</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B195">195</xref>]</td>
    </tr>
    <tr>
      <td rowspan="2">Tongxinluo</td>
      <td>GPX4, FSP1, ACSL4</td>
      <td>COPD</td>
      <td>[<xref ref-type="bibr" rid="B196">196</xref>]</td>
    </tr>
    <tr>
      <td>Beclin-1-Induced Autophagy</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B197">197</xref>]</td>
    </tr>
    <tr>
      <td>Qing-Xin-Jie-Yu Granule</td>
      <td>System xc-/GPX4</td>
      <td>Atherosclerosis</td>
      <td>[<xref ref-type="bibr" rid="B198">198</xref>]</td>
    </tr>
  </tbody>
</table>
        <table-wrap-foot>
          <fn id="t1FN1">
            <p>AMPK: AMP-activated protein kinase; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1; GPX4: glutathione peroxidase 4; ACSL4: acyl-CoA synthetase long-chain family member 4; p53: tumor suppressor p53; DMT1: divalent metal transporter 1; FSP1: ferroptosis suppressor protein 1; ERK: extracellular signal-regulated kinase; Keap1: Kelch-like ECH-associated protein 1; PPARγ: peroxisome proliferator-activated receptor gamma; STAT3: signal transducer and activator of transcription 3; PI3K-AKT-mTOR: phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR); PTGS2: prostaglandin-endoperoxide synthase 2; ALOX15: arachidonate 15-lipoxygenase; Mtdh: metadherin; BMP: bone morphogenetic protein; MAPK: mitogen-activated protein kinase; System xc-: cystine/glutamate antiporter; SLC7A11: solute carrier family 7 member 11; CB2R: cannabinoid receptor 2; HMOX1: heme oxygenase 1; SLC40A1: solute carrier family 40 member 1; FTH1: ferritin heavy chain 1; SOCS1: suppressor of cytokine signaling 1; COPD: chronic obstructive pulmonary disease; CeCH NPs: Ceria Nanozyme Coordination with Curcumin Nanoparticles.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <sec id="sec4-1">
        <title>Organic compounds</title>
        <p>Several small molecules and biologics have been reported to suppress macrophage ferroptosis, suggesting a broader therapeutic repertoire beyond conventional lipid-lowering drugs<sup>[<xref ref-type="bibr" rid="B164">164</xref>]</sup>. Recent studies have revealed that certain drug agents and proteins can hinder macrophage ferroptosis, thereby demonstrating their anti-atherosclerotic potential through the inhibition of this process.</p>
        <p>One study has shown that Metformin inhibits foam cell formation, the inflammatory response, and ferroptosis in ox-LDL-treated macrophages via the AMPK/extracellular signal-regulated kinase (ERK) signaling pathway, thereby contributing to its anti-atherosclerotic effect<sup>[<xref ref-type="bibr" rid="B162">162</xref>]</sup>. Dexmedetomidine, an α-adrenergic receptor agonist, has shown promising pharmacological effects in CVDs, such as the enhancement of myocardial ischemia-reperfusion<sup>[<xref ref-type="bibr" rid="B165">165</xref>]</sup>. Further studies revealed that Dexmedetomidine promotes M2 macrophage polarization, reduces inflammation, and inhibits hepatic innate immune activation via the macrophage peroxisome proliferator-activated receptor gamma (PPARγ)/STAT3 pathway<sup>[<xref ref-type="bibr" rid="B166">166</xref>]</sup>. In addition, Dexmedetomidine has been reported to exhibit anti-ferroptotic and antioxidant effects through upregulation of the Nrf2/GPX4 pathway<sup>[<xref ref-type="bibr" rid="B167">167</xref>]</sup>, suggesting its potential to inhibit macrophage ferroptosis and promote macrophage M2 polarization. Itaconate is a metabolite generated during inflammatory macrophage activation that activates Nrf2 via the alkylation of Keap1<sup>[<xref ref-type="bibr" rid="B168">168</xref>]</sup>, and has been shown to inhibit atherosclerosis by inducing Nrf2-dependent inhibition of proinflammatory responses in macrophages<sup>[<xref ref-type="bibr" rid="B169">169</xref>]</sup>. Itaconate also alleviates lipopolysaccharide-induced acute lung injury by inhibiting macrophage ferroptosis in an Nrf2-dependent manner<sup>[<xref ref-type="bibr" rid="B170">170</xref>]</sup>. Uridine, recognized for its antioxidant properties, has been found to alleviate sepsis-induced acute lung injury by inhibiting macrophage ferroptosis<sup>[<xref ref-type="bibr" rid="B171">171</xref>]</sup>. Additionally, Fer-1 and iron chelators have been effective in preventing ferroptosis in macrophages infected with Mycobacterium tuberculosis<sup>[<xref ref-type="bibr" rid="B172">172</xref>]</sup>. Thymosin β4, an endogenous iron chelator involved in iron homeostasis, inhibits erastin and glutamate-induced ferroptosis in macrophage lines by upregulating GPX4 expression<sup>[<xref ref-type="bibr" rid="B173">173</xref>]</sup>. Moreover, the alleviation of non-alcoholic fatty liver disease (NAFLD) by inhibition of ferroptosis through up-regulation of GPX4 by Thymosin β4 has also been demonstrated<sup>[<xref ref-type="bibr" rid="B174">174</xref>]</sup>. Furthermore, the increase of semaphorin 5A in the synovial fluid of patients with rheumatoid arthritis, mainly originating from CD68<sup>+</sup> synovial macrophages, has been shown to inhibit ferroptosis in synovial fibroblasts, ameliorating rheumatoid arthritis by the activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway and increasing GPX4 expression<sup>[<xref ref-type="bibr" rid="B175">175</xref>]</sup>. In summary, recent studies have shown that inhibiting macrophage ferroptosis has broad applications in anti-atherosclerotic therapy. The above evidence suggests that organic compounds such as dexmedetomidine, itaconate, uridine, and thymosin β4 can modulate macrophage ferroptosis through distinct signaling pathways and show great potential for anti-atherosclerotic therapy.</p>
      </sec>
      <sec id="sec4-2">
        <title>Natural botanical extracts and derivatives</title>
        <p>Compounds derived from natural plants have increasingly garnered attention as prospective pharmaceuticals due to their accessibility, minimal side effects, and notable biological activities<sup>[<xref ref-type="bibr" rid="B176">176</xref>]</sup>. A study by Zeng <italic>et al.</italic> indicated that puerarin alleviates lipopolysaccharide-induced ferroptosis in RAW264.7 macrophages through pathways including tryptophan, arachidonic acid, and GSH metabolism, thereby exhibiting anti-inflammatory properties<sup>[<xref ref-type="bibr" rid="B177">177</xref>]</sup>. Similarly, Micheliolide, a compound derived from chamomile, has been identified for its antioxidant and anti-inflammatory effects<sup>[<xref ref-type="bibr" rid="B178">178</xref>]</sup>. Luo <italic>et al.</italic> reported that Micheliolide inhibits macrophage ferroptosis by targeting the Keap1/Nrf2 interaction, consequently reducing atherosclerosis severity<sup>[<xref ref-type="bibr" rid="B138">138</xref>]</sup>. Sulforaphane also inhibits ox-LDL-induced lipid accumulation in macrophages and facilitates ABCA1/G1-mediated cholesterol efflux, thereby alleviating the extent of atherosclerosis<sup>[<xref ref-type="bibr" rid="B179">179</xref>]</sup>. Furthermore, it was confirmed that Sulforaphane can stimulate Nrf2 in macrophages, forming the basis of its anti-atherosclerotic activity. Another study demonstrated that Sulforaphane is a potent Nrf2 activator that facilitates nuclear translocation of Nrf2, upregulates the levels of ferritin and SLC7A11, and inhibits lipid peroxidation and ferroptosis<sup>[<xref ref-type="bibr" rid="B180">180</xref>]</sup>. Naringenin, a natural flavonoid present in various plants, similarly prevents cholesterol-induced atherosclerosis in LDL receptor knockout (homozygous deficient mice, LDLR<sup>-/-</sup>) mice by reducing macrophage foam cell formation and inflammation<sup>[<xref ref-type="bibr" rid="B181">181</xref>]</sup>. In addition, Naringenin enhances macrophage M2 polarization, reduces macrophage recruitment, and inhibits inducible nitric oxide synthase (iNOS) expression<sup>[<xref ref-type="bibr" rid="B182">182</xref>,<xref ref-type="bibr" rid="B183">183</xref>]</sup>. In a subsequent study, researchers found that Naringenin not only inhibited ferroptosis but also alleviated myocardial ischemia/reperfusion injury through the Nrf2/System xc-/GPX4 pathway<sup>[<xref ref-type="bibr" rid="B184">184</xref>]</sup>. Furthermore, other studies also reported the anti-ferroptosis effect of Naringenin<sup>[<xref ref-type="bibr" rid="B185">185</xref>]</sup>. These findings collectively indicate that NAR has the potential to inhibit macrophage ferroptosis, thereby attenuating atherosclerosis.</p>
        <p>Ferroptosis is responsible for the polarization of M1 macrophages<sup>[<xref ref-type="bibr" rid="B186">186</xref>]</sup>. Quercetin, a natural dietary flavonoid, exerts anti-inflammatory and anti-ferroptosis effects across various diseases. The study by Wang <italic>et al.</italic> developed a model of lipopolysaccharide-induced macrophage ferroptosis, revealing Quercetin’s effectiveness in counteracting ferroptosis during the inflammatory state in macrophages<sup>[<xref ref-type="bibr" rid="B187">187</xref>]</sup>. Furthermore, Quercetin mitigates neutrophil airway inflammation, inhibits M1 macrophage polarization, and acts as a potential macrophage ferroptosis inhibitor<sup>[<xref ref-type="bibr" rid="B187">187</xref>]</sup>. Additional research indicates that ferroptotic cells induce a pro-inflammatory state by triggering macrophage recruitment via C-C motif chemokine ligand 2 (CCL2), and that Quercetin inhibits ferroptosis-driven inflammation, thereby reducing inflammation-induced kidney damage<sup>[<xref ref-type="bibr" rid="B188">188</xref>]</sup>. Previous research has shown that combining Ceria Nanozyme Coordination with Curcumin to create Ceria Nanozyme Coordination with Curcumin Nanoparticles (CeCH NPs) effectively promotes M2 macrophage polarization and inhibits ferroptosis in a lipopolysaccharide-induced sepsis model, which significantly alleviates myocardial injury and thus restores cardiac function<sup>[<xref ref-type="bibr" rid="B189">189</xref>]</sup>. Wu <italic>et al.</italic> found that β-caryophyllene, a natural bicyclic sesquiterpene effectively reduces macrophage lipid peroxidation, decreases the levels of pro-ferritin factors, and increases the levels of anti-ferritin factors in RAS-selective lethal small molecule 3 (RSL3)-reduced macrophages, suggesting that β-caryophyllene had an anti-ferroptosis inhibitory effect on macrophage ferroptosis<sup>[<xref ref-type="bibr" rid="B190">190</xref>]</sup>. Additionally, baicalein enhances GPX4 expression in macrophages and inhibits ferroptosis, protecting macrophages from ferroptosis and rescuing phagocytosis in endometriosis<sup>[<xref ref-type="bibr" rid="B191">191</xref>]</sup>. Liensinine, a bioactive ingredient extracted from <italic>Lotus corniculatus</italic><sup>[<xref ref-type="bibr" rid="B192">192</xref>]</sup>, has emerged as a novel ferroptosis inhibitor that attenuates ferroptosis in acute liver injury by blocking autophagosome-lysosome fusion and inhibiting iron autophagy, thereby restoring macrophage phenotypic homeostasis and reducing acute liver injury<sup>[<xref ref-type="bibr" rid="B193">193</xref>]</sup>. Jing-Fang n-butanol extract (JFNE) and its active component (JFNE-C) inhibit lipopolysaccharide-induced ferroptosis in RAW264.7 macrophages via the STAT3/p53/SLC7A11 signaling pathway<sup>[<xref ref-type="bibr" rid="B194">194</xref>]</sup>.</p>
      </sec>
      <sec id="sec4-3">
        <title>Compound formulations</title>
        <p>In addition to natural phytomedicine monomers, some compound formulations have also been found to have anti-ferroptosis effects. Studies have shown that the traditional Chinese medicine Maijitong granule is effective in treating CVDs. Maijitong granule inhibits the progression of atherosclerosis by suppressing ferroptosis in peritoneal macrophages, thereby reducing lipid peroxidation and dysregulation of iron homeostasis. Mechanistically, STAT6 negatively regulates ferroptosis by transcriptionally inhibiting suppressor of cytokine signaling 1 (SOCS1)/p53 and DMT1, further highlighting the critical role of inhibiting macrophage ferroptosis in suppressing atherosclerosis<sup>[<xref ref-type="bibr" rid="B195">195</xref>]</sup>. Research has indicated that Tongxinluo inhibits ferroptosis by increasing the expression of the GPX4 and FSP1 mRNA and protein levels as well as decreasing the protein expression of ACSL4. This action helps delay the progression of atherosclerosis to prevent cardiovascular events<sup>[<xref ref-type="bibr" rid="B196">196</xref>]</sup>. In addition, Tongxinluo can increase plaque stability and exert anti-atherosclerotic effects by inhibiting ox-LDL-induced lipid deposition in macrophages<sup>[<xref ref-type="bibr" rid="B197">197</xref>]</sup>. This evidence suggests that Tongxinluo has multiple effects, inhibiting ferroptosis and attenuating macrophage lipid deposition. Thus, it has the potential to alleviate atherosclerosis by inhibiting ferroptosis and reducing macrophage foaming. Additionally, the regulation of macrophage ferroptosis is a critical mechanism through which Qing-Xin-Jie-Yu Granule stabilizes atherosclerosis-vulnerable plaques. Qing-Xin-Jie-Yu Granule has also been shown to alleviate atherosclerosis in aortic plaques and reduce macrophage ferroptosis by mediating the System xc-/GPX4 signaling pathway<sup>[<xref ref-type="bibr" rid="B198">198</xref>]</sup>.</p>
      </sec>
    </sec>
    <sec id="sec5">
      <title>PERSPECTIVE AND CONCLUSION</title>
      <p>Macrophage ferroptosis plays a key role in linking iron metabolism dysregulation, lipid peroxidation, and inflammatory amplification in atherosclerosis. Among the emerging mechanisms associated with disease progression, this finding provides deeper insights into atherosclerosis and reveals the interplay between iron metabolism, lipid peroxidation, and inflammatory amplification within the atherosclerotic microenvironment. This concept deepens our understanding of how macrophage dysfunction leads to plaque formation, growth, and instability.</p>
      <p>However, the major gaps still remain: The subtype-specific susceptibility of plaque macrophages to ferroptosis. The causal relationship between ferroptosis and plaque stability. The translational feasibility of ferroptosis-targeted therapies.</p>
      <p>Nevertheless, the therapeutic outlook is highly promising. In particular, agents targeting the GPX4 axis and the Nrf2 signaling pathway may offer substantial clinical potential by restoring redox balance, suppressing lipid peroxidation, and enhancing macrophage survival and function. Future work should define subtype-specific ferroptotic programs in macrophages, validate causal links <italic>in vivo</italic>, and evaluate the efficacy and safety of GPX4/Nrf2-based interventions.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>DECLARATIONS</title>
      <sec>
        <title>Acknowledgments</title>
        <p>The Graphical Abstract was created in BioRender. Fan, F. (2026) <uri xlink:href="https://BioRender.com/n02c554">https://BioRender.com/n02c554</uri>.</p>
      </sec>
      <sec>
        <title>Authors’ contributions</title>
        <p>Writing - original draft: Shi J, Fan F, Wang J</p>
        <p>Writing - review and editing: Zheng G, Zhang R</p>
        <p>Conceptualization, and project administration and supervision: Wang Y, Guo L, Zhang X, Ma C</p>
      </sec>
      <sec>
        <title>Availability of data and materials</title>
        <p>Not applicable.</p>
      </sec>
      <sec>
        <title>AI and AI-assisted tools statement</title>
        <p>During the preparation of this manuscript, the AI tool ChatGPT (version 3.0, released 2020-06-11) was used solely for language editing. The tools did not influence the study design, data collection, analysis, interpretation, or the scientific content of the work. All authors take full responsibility for the accuracy, integrity, and final content of the manuscript.</p>
      </sec>
      <sec>
        <title>Financial support and sponsorship</title>
        <p>This work was supported by the Scientific Research Program of Tianjin Education Commission (2024ZD006).</p>
      </sec>
      <sec>
        <title>Conflicts of interest</title>
        <p>All authors declared that there are no conflicts of interest.</p>
      </sec>
      <sec>
        <title>Ethical approval and consent to participate</title>
        <p>Not applicable.</p>
      </sec>
      <sec>
        <title>Consent for publication</title>
        <p>Not applicable.</p>
      </sec>
      <sec>
        <title>Copyright</title>
        <p>© The Author(s) 2026.</p>
      </sec>
    </sec>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valk</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hammill</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grip</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Saturated fat: villain and bogeyman in the development of cardiovascular disease? <italic>Eur J of Prev Cardiol.</italic> 2022;29:2312-21</article-title>
          <pub-id pub-id-type="doi">10.1093/eurjpc/zwac194</pub-id>
          <pub-id pub-id-type="pmid">36059207</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cafaro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Perricone</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gerli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bartoloni</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular risk in systemic autoimmune diseases</article-title>
          <source>Lancet.</source>
          <year>2023</year>
          <volume>401</volume>
          <fpage>21</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(22)02477-1</pub-id>
          <pub-id pub-id-type="pmid">36610763</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Sheedy</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Macrophages in atherosclerosis: a dynamic balance</article-title>
          <source>Nat Rev Immunol.</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>709</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3520</pub-id>
          <pub-id pub-id-type="pmid">23995626</pub-id>
          <pub-id pub-id-type="pmcid">PMC4357520</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Horng</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Lipid metabolism in regulation of macrophage functions</article-title>
          <source>Trends Cell Biol.</source>
          <year>2020</year>
          <volume>30</volume>
          <fpage>979</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tcb.2020.09.006</pub-id>
          <pub-id pub-id-type="pmid">33036870</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dixon</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Lemberg</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Lamprecht</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title>
          <source>Cell.</source>
          <year>2012</year>
          <volume>149</volume>
          <fpage>1060</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id>
          <pub-id pub-id-type="pmid">22632970</pub-id>
          <pub-id pub-id-type="pmcid">PMC3367386</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ouyang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhi</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ferroptosis: the potential value target in atherosclerosis</article-title>
          <source>Cell Death Dis.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>782</fpage>
          <pub-id pub-id-type="doi">10.1038/s41419-021-04054-3</pub-id>
          <pub-id pub-id-type="pmid">34376636</pub-id>
          <pub-id pub-id-type="pmcid">PMC8355346</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage polarization and metabolism in atherosclerosis</article-title>
          <source>Cell Death Dis.</source>
          <year>2023</year>
          <volume>14</volume>
          <fpage>691</fpage>
          <pub-id pub-id-type="doi">10.1038/s41419-023-06206-z</pub-id>
          <pub-id pub-id-type="pmid">37863894</pub-id>
          <pub-id pub-id-type="pmcid">PMC10589261</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Meyer</surname>
              <given-names>GRY</given-names>
            </name>
            <name>
              <surname>Zurek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Puylaert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martinet</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets</article-title>
          <source>Nat Rev Cardiol.</source>
          <year>2024</year>
          <volume>21</volume>
          <fpage>312</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1038/s41569-023-00957-0</pub-id>
          <pub-id pub-id-type="pmid">38163815</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage subsets and death are responsible for atherosclerotic plaque formation</article-title>
          <source>Front Immunol.</source>
          <year>2022</year>
          <volume>13</volume>
          <fpage>843712</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2022.843712</pub-id>
          <pub-id pub-id-type="pmid">35432323</pub-id>
          <pub-id pub-id-type="pmcid">PMC9007036</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tokgözoğlu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The dawn of a new era of targeted lipid-lowering therapies</article-title>
          <source>Eur Heart J.</source>
          <year>2022</year>
          <volume>43</volume>
          <fpage>3198</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehab841</pub-id>
          <pub-id pub-id-type="pmid">35051271</pub-id>
          <pub-id pub-id-type="pmcid">PMC9448630</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carthew</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Sontheimer</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Origins and mechanisms of miRNAs and siRNAs</article-title>
          <source>Cell.</source>
          <year>2009</year>
          <volume>136</volume>
          <fpage>642</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2009.01.035</pub-id>
          <pub-id pub-id-type="pmid">19239886</pub-id>
          <pub-id pub-id-type="pmcid">PMC2675692</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Crooke</surname>
              <given-names>ST</given-names>
            </name>
          </person-group>
          <article-title>RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus</article-title>
          <source>Mol Ther.</source>
          <year>2017</year>
          <volume>25</volume>
          <fpage>2075</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ymthe.2017.06.002</pub-id>
          <pub-id pub-id-type="pmid">28663102</pub-id>
          <pub-id pub-id-type="pmcid">PMC5589097</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landlinger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pouwer</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Juno</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE<sup>*</sup>3Leiden.CETP mice</article-title>
          <source>Eur Heart J.</source>
          <year>2017</year>
          <volume>38</volume>
          <fpage>2499</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehx260</pub-id>
          <pub-id pub-id-type="pmid">28637178</pub-id>
          <pub-id pub-id-type="pmcid">PMC5837708</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lintner</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>McClure</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain</article-title>
          <source>PLoS Biol.</source>
          <year>2017</year>
          <volume>15</volume>
          <fpage>e2001882</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pbio.2001882</pub-id>
          <pub-id pub-id-type="pmid">28323820</pub-id>
          <pub-id pub-id-type="pmcid">PMC5360235</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nordestgaard</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Langsted</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Tybjærg-Hansen</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Advances in lipid-lowering therapy through gene-silencing technologies</article-title>
          <source>Nat Rev Cardiol.</source>
          <year>2018</year>
          <volume>15</volume>
          <fpage>261</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1038/nrcardio.2018.3</pub-id>
          <pub-id pub-id-type="pmid">29417937</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishikido</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
          <article-title>Non-antibody approaches to proprotein convertase subtilisin kexin 9 inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries</article-title>
          <source>Front Cardiovasc Med.</source>
          <year>2019</year>
          <volume>5</volume>
          <fpage>199</fpage>
          <pub-id pub-id-type="doi">10.3389/fcvm.2018.00199</pub-id>
          <pub-id pub-id-type="pmid">30761308</pub-id>
          <pub-id pub-id-type="pmcid">PMC6361748</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Curtale</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Diversity, mechanisms, and significance of macrophage plasticity</article-title>
          <source>Annu Rev Pathol Mech Dis.</source>
          <year>2020</year>
          <volume>15</volume>
          <fpage>123</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012418-012718</pub-id>
          <pub-id pub-id-type="pmid">31530089</pub-id>
          <pub-id pub-id-type="pmcid">PMC7176483</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bornfeldt</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
          <article-title>Macrophage phenotype and function in different stages of atherosclerosis</article-title>
          <source>Circ Res.</source>
          <year>2016</year>
          <volume>118</volume>
          <fpage>653</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306256</pub-id>
          <pub-id pub-id-type="pmid">26892964</pub-id>
          <pub-id pub-id-type="pmcid">PMC4762068</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garlanda</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Locati</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Macrophage diversity and polarization in atherosclerosis: a question of balance</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>1419</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.108.180497</pub-id>
          <pub-id pub-id-type="pmid">19696407</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lafuse</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Wozniak</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Rajaram</surname>
              <given-names>MVS</given-names>
            </name>
          </person-group>
          <article-title>Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair</article-title>
          <source>Cells.</source>
          <year>2020</year>
          <volume>10</volume>
          <fpage>51</fpage>
          <pub-id pub-id-type="doi">10.3390/cells10010051</pub-id>
          <pub-id pub-id-type="pmid">33396359</pub-id>
          <pub-id pub-id-type="pmcid">PMC7824389</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shapouri-Moghaddam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mohammadian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vazini</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage plasticity, polarization, and function in health and disease</article-title>
          <source>J Cell Physiol.</source>
          <year>2018</year>
          <volume>233</volume>
          <fpage>6425</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.26429</pub-id>
          <pub-id pub-id-type="pmid">29319160</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chistiakov</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Bobryshev</surname>
              <given-names>YV</given-names>
            </name>
            <name>
              <surname>Orekhov</surname>
              <given-names>AN</given-names>
            </name>
          </person-group>
          <article-title>Changes in transcriptome of macrophages in atherosclerosis</article-title>
          <source>J Cell Mol Med.</source>
          <year>2015</year>
          <volume>19</volume>
          <fpage>1163</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1111/jcmm.12591</pub-id>
          <pub-id pub-id-type="pmid">25973901</pub-id>
          <pub-id pub-id-type="pmcid">PMC4459832</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liberale</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dallegri</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Montecucco</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Carbone</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiological relevance of macrophage subsets in atherogenesis</article-title>
          <source>Thromb Haemost.</source>
          <year>2017</year>
          <volume>117</volume>
          <fpage>7</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1160/TH16-08-0593</pub-id>
          <pub-id pub-id-type="pmid">27683760</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kadl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Meher</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>PR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2</article-title>
          <source>Circ Res.</source>
          <year>2010</year>
          <volume>107</volume>
          <fpage>737</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.215715</pub-id>
          <pub-id pub-id-type="pmid">20651288</pub-id>
          <pub-id pub-id-type="pmcid">PMC2941538</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gleissner</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>von Hundelshausen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Platelet chemokines in vascular disease</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2008</year>
          <volume>28</volume>
          <fpage>1920</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.108.169417</pub-id>
          <pub-id pub-id-type="pmid">18723831</pub-id>
          <pub-id pub-id-type="pmcid">PMC2657037</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Domschke</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gleissner</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>CXCL4-induced macrophages in human atherosclerosis</article-title>
          <source>Cytokine.</source>
          <year>2019</year>
          <volume>122</volume>
          <fpage>154141</fpage>
          <pub-id pub-id-type="doi">10.1016/j.cyto.2017.08.021</pub-id>
          <pub-id pub-id-type="pmid">28899579</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gleissner</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Shaked</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Erbel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Böckler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Katus</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages</article-title>
          <source>Circ Res.</source>
          <year>2010</year>
          <volume>106</volume>
          <fpage>203</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.199505</pub-id>
          <pub-id pub-id-type="pmid">19910578</pub-id>
          <pub-id pub-id-type="pmcid">PMC2876722</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finn</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Polavarapu</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques</article-title>
          <source>J Am Coll Cardiol.</source>
          <year>2012</year>
          <volume>59</volume>
          <fpage>166</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2011.10.852</pub-id>
          <pub-id pub-id-type="pmid">22154776</pub-id>
          <pub-id pub-id-type="pmcid">PMC3253238</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leitinger</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schulman</surname>
              <given-names>IG</given-names>
            </name>
          </person-group>
          <article-title>Phenotypic polarization of macrophages in atherosclerosis</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2013</year>
          <volume>33</volume>
          <fpage>1120</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300173</pub-id>
          <pub-id pub-id-type="pmid">23640492</pub-id>
          <pub-id pub-id-type="pmcid">PMC3745999</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stöger</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Goossens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>de Winther</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Macrophage heterogeneity: relevance and functional implications in atherosclerosis</article-title>
          <source>Curr Vasc Pharmacol.</source>
          <year>2010</year>
          <volume>8</volume>
          <fpage>233</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.2174/157016110790886983</pub-id>
          <pub-id pub-id-type="pmid">20180776</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farahi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Lusis</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Roles of macrophages in atherogenesis</article-title>
          <source>Front Pharmacol.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>785220</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2021.785220</pub-id>
          <pub-id pub-id-type="pmid">34899348</pub-id>
          <pub-id pub-id-type="pmcid">PMC8660976</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Tabas</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>The response-to-retention hypothesis of early atherogenesis</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>1995</year>
          <volume>15</volume>
          <fpage>551</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="doi">10.1161/01.atv.15.5.551</pub-id>
          <pub-id pub-id-type="pmid">7749869</pub-id>
          <pub-id pub-id-type="pmcid">PMC2924812</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Insights from pre-clinical and clinical studies on the role of innate inflammation in atherosclerosis regression</article-title>
          <source>Front Cardiovasc Med.</source>
          <year>2018</year>
          <volume>5</volume>
          <fpage>32</fpage>
          <pub-id pub-id-type="doi">10.3389/fcvm.2018.00032</pub-id>
          <pub-id pub-id-type="pmid">29868610</pub-id>
          <pub-id pub-id-type="pmcid">PMC5958627</pub-id>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barrett</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <article-title>Macrophages in atherosclerosis regression</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2020</year>
          <volume>40</volume>
          <fpage>20</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.312802</pub-id>
          <pub-id pub-id-type="pmid">31722535</pub-id>
          <pub-id pub-id-type="pmcid">PMC6946104</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Huo</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1/TLR4/STAT3 axis in M1 macrophages</article-title>
          <source>Redox Biol.</source>
          <year>2024</year>
          <volume>75</volume>
          <fpage>103255</fpage>
          <pub-id pub-id-type="doi">10.1016/j.redox.2024.103255</pub-id>
          <pub-id pub-id-type="pmid">39029270</pub-id>
          <pub-id pub-id-type="pmcid">PMC11304870</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosmidou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Efstathiou</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Hoang</surname>
              <given-names>MV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Issues with the specificity of immunological reagents for NLRP3: implications for age-related macular degeneration</article-title>
          <source>Sci Rep.</source>
          <year>2018</year>
          <volume>8</volume>
          <fpage>461</fpage>
          <pub-id pub-id-type="doi">10.1038/s41598-017-17634-1</pub-id>
          <pub-id pub-id-type="pmid">29323137</pub-id>
          <pub-id pub-id-type="pmcid">PMC5764999</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chinetti-Gbaguidi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Staels</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Macrophage phenotypes in atherosclerosis</article-title>
          <source>Immunol Rev.</source>
          <year>2014</year>
          <volume>262</volume>
          <fpage>153</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="doi">10.1111/imr.12218</pub-id>
          <pub-id pub-id-type="pmid">25319333</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dollery</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Atherosclerosis and proteinase activation</article-title>
          <source>Cardiovasc Res.</source>
          <year>2006</year>
          <volume>69</volume>
          <fpage>625</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cardiores.2005.11.003</pub-id>
          <pub-id pub-id-type="pmid">16376322</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lancaster</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Iron macrophages: dance of death and MMP release in intraplaque hemorrhage</article-title>
          <source>Thromb Haemost.</source>
          <year>2024</year>
          <volume>124</volume>
          <fpage>581</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0043-1778071</pub-id>
          <pub-id pub-id-type="pmid">38196076</pub-id>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Purushothaman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Purushothaman</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Plaque neovascularization: defense mechanisms, betrayal, or a war in progress</article-title>
          <source>Ann N Y Acad Sci.</source>
          <year>2012</year>
          <volume>1254</volume>
          <fpage>7</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06497.x</pub-id>
          <pub-id pub-id-type="pmid">22548565</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Puylaert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Van Praet</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques</article-title>
          <source>Angiogenesis.</source>
          <year>2023</year>
          <volume>26</volume>
          <fpage>505</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1007/s10456-023-09877-6</pub-id>
          <pub-id pub-id-type="pmid">37120604</pub-id>
          <pub-id pub-id-type="pmcid">PMC10542744</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage ferroptosis promotes MMP2/9 overexpression induced by hemin in hemorrhagic plaque</article-title>
          <source>Thromb Haemost.</source>
          <year>2023</year>
          <volume>124</volume>
          <fpage>568</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1055/a-2173-3602</pub-id>
          <pub-id pub-id-type="pmid">37696298</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Akahori</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Harari</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CD163<sup>+</sup> macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis</article-title>
          <source>J Clin Invest.</source>
          <year>2018</year>
          <volume>128</volume>
          <fpage>1106</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI93025</pub-id>
          <pub-id pub-id-type="pmid">29457790</pub-id>
          <pub-id pub-id-type="pmcid">PMC5824873</pub-id>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stöger</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Gijbels</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>van der Velden</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Distribution of macrophage polarization markers in human atherosclerosis</article-title>
          <source>Atherosclerosis.</source>
          <year>2012</year>
          <volume>225</volume>
          <fpage>461</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.09.013</pub-id>
          <pub-id pub-id-type="pmid">23078881</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peled</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Dynamic aspects of macrophage polarization during atherosclerosis progression and regression</article-title>
          <source>Front Immunol.</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>579</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2014.00579</pub-id>
          <pub-id pub-id-type="pmid">25429291</pub-id>
          <pub-id pub-id-type="pmcid">PMC4228913</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khallou-Laschet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Varthaman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fornasa</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage plasticity in experimental atherosclerosis</article-title>
          <source>PLoS One.</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>e8852</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0008852</pub-id>
          <pub-id pub-id-type="pmid">20111605</pub-id>
          <pub-id pub-id-type="pmcid">PMC2810335</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaipersad</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Lip</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Silverman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shantsila</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The role of monocytes in angiogenesis and atherosclerosis</article-title>
          <source>J Am Coll Cardiol.</source>
          <year>2014</year>
          <volume>63</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.019</pub-id>
          <pub-id pub-id-type="pmid">24140662</pub-id>
        </element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epelman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lavine</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Origin and functions of tissue macrophages</article-title>
          <source>Immunity.</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>21</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.013</pub-id>
          <pub-id pub-id-type="pmid">25035951</pub-id>
          <pub-id pub-id-type="pmcid">PMC4470379</pub-id>
        </element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narasimhan</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Marcovecchio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>AAJ</given-names>
            </name>
            <name>
              <surname>Hedrick</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Nonclassical monocytes in health and disease</article-title>
          <source>Annu Rev Immunol.</source>
          <year>2019</year>
          <volume>37</volume>
          <fpage>439</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053119</pub-id>
          <pub-id pub-id-type="pmid">31026415</pub-id>
        </element-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pham</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Dang</surname>
              <given-names>CP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endocytosis of red blood cell extracellular vesicles by macrophages leads to cytoplasmic heme release and prevents foam cell formation in atherosclerosis</article-title>
          <source>J Extracell Vesicles.</source>
          <year>2023</year>
          <volume>12</volume>
          <fpage>12354</fpage>
          <pub-id pub-id-type="doi">10.1002/jev2.12354</pub-id>
          <pub-id pub-id-type="pmid">37553837</pub-id>
          <pub-id pub-id-type="pmcid">PMC10410060</pub-id>
        </element-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chinetti-Gbaguidi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Colin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Staels</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Macrophage subsets in atherosclerosis</article-title>
          <source>Nat Rev Cardiol.</source>
          <year>2015</year>
          <volume>12</volume>
          <fpage>10</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1038/nrcardio.2014.173</pub-id>
          <pub-id pub-id-type="pmid">25367649</pub-id>
        </element-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chistiakov</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Melnichenko</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Myasoedova</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Grechko</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Orekhov</surname>
              <given-names>AN</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of foam cell formation in atherosclerosis</article-title>
          <source>J Mol Med.</source>
          <year>2017</year>
          <volume>95</volume>
          <fpage>1153</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1007/s00109-017-1575-8</pub-id>
          <pub-id pub-id-type="pmid">28785870</pub-id>
        </element-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Lysosomal acid lipase in lipid metabolism and beyond</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2019</year>
          <volume>39</volume>
          <fpage>850</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.312136</pub-id>
          <pub-id pub-id-type="pmid">30866656</pub-id>
          <pub-id pub-id-type="pmcid">PMC6482091</pub-id>
        </element-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms and regulation of cholesterol homeostasis</article-title>
          <source>Nat Rev Mol Cell Biol.</source>
          <year>2019</year>
          <volume>21</volume>
          <fpage>225</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1038/s41580-019-0190-7</pub-id>
          <pub-id pub-id-type="pmid">31848472</pub-id>
        </element-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maxfield</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Tabas</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Role of cholesterol and lipid organization in disease</article-title>
          <source>Nature.</source>
          <year>2005</year>
          <volume>438</volume>
          <fpage>612</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1038/nature04399</pub-id>
          <pub-id pub-id-type="pmid">16319881</pub-id>
        </element-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O’Neill</surname>
              <given-names>LAJ</given-names>
            </name>
            <name>
              <surname>Kishton</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Rathmell</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A guide to immunometabolism for immunologists</article-title>
          <source>Nat Rev Immunol.</source>
          <year>2016</year>
          <volume>16</volume>
          <fpage>553</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1038/nri.2016.70</pub-id>
          <pub-id pub-id-type="pmid">27396447</pub-id>
          <pub-id pub-id-type="pmcid">PMC5001910</pub-id>
        </element-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Chandel</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial control of immunity: beyond ATP</article-title>
          <source>Nat Rev Immunol.</source>
          <year>2017</year>
          <volume>17</volume>
          <fpage>608</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1038/nri.2017.66</pub-id>
          <pub-id pub-id-type="pmid">28669986</pub-id>
        </element-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adeva-Andany</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Carneiro-Freire</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Seco-Filgueira</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fernández-Fernández</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mouriño-Bayolo</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial β-oxidation of saturated fatty acids in humans</article-title>
          <source>Mitochondrion.</source>
          <year>2019</year>
          <volume>46</volume>
          <fpage>73</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mito.2018.02.009</pub-id>
          <pub-id pub-id-type="pmid">29551309</pub-id>
        </element-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>de Siqueira Mendes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>de Campos Crispin</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Norata</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Newsholme</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>A past and present overview of macrophage metabolism and functional outcomes</article-title>
          <source>Clin Sci.</source>
          <year>2017</year>
          <volume>131</volume>
          <fpage>1329</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1042/CS20170220</pub-id>
          <pub-id pub-id-type="pmid">28592702</pub-id>
        </element-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Loike</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kako</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lipoprotein lipase regulates Fc receptor-mediated phagocytosis by macrophages maintained in glucose-deficient medium</article-title>
          <source>J Clin Invest.</source>
          <year>1997</year>
          <volume>100</volume>
          <fpage>649</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI119576</pub-id>
          <pub-id pub-id-type="pmid">9239412</pub-id>
          <pub-id pub-id-type="pmcid">PMC508233</pub-id>
        </element-citation>
      </ref>
      <ref id="B61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Everts</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ivanova</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages</article-title>
          <source>Nat Immunol.</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>846</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2956</pub-id>
          <pub-id pub-id-type="pmid">25086775</pub-id>
          <pub-id pub-id-type="pmcid">PMC4139419</pub-id>
        </element-citation>
      </ref>
      <ref id="B62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vats</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mukundan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Odegaard</surname>
              <given-names>JI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation</article-title>
          <source>Cell Metab.</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>13</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2006.05.011</pub-id>
          <pub-id pub-id-type="pmid">16814729</pub-id>
          <pub-id pub-id-type="pmcid">PMC1904486</pub-id>
        </element-citation>
      </ref>
      <ref id="B63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nomura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>ZX</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage fatty acid oxidation inhibits atherosclerosis progression</article-title>
          <source>J Mol Cell Cardiol.</source>
          <year>2019</year>
          <volume>127</volume>
          <fpage>270</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.yjmcc.2019.01.003</pub-id>
          <pub-id pub-id-type="pmid">30639412</pub-id>
          <pub-id pub-id-type="pmcid">PMC9124604</pub-id>
        </element-citation>
      </ref>
      <ref id="B64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nomura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rovira</surname>
              <given-names>II</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fatty acid oxidation in macrophage polarization</article-title>
          <source>Nat Immunol.</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>216</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3366</pub-id>
          <pub-id pub-id-type="pmid">26882249</pub-id>
          <pub-id pub-id-type="pmcid">PMC6033271</pub-id>
        </element-citation>
      </ref>
      <ref id="B65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hohensinner</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Lenz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haider</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacological inhibition of fatty acid oxidation reduces atherosclerosis progression by suppression of macrophage NLRP3 inflammasome activation</article-title>
          <source>Biochem Pharmacol.</source>
          <year>2021</year>
          <volume>190</volume>
          <fpage>114634</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2021.114634</pub-id>
          <pub-id pub-id-type="pmid">34058186</pub-id>
        </element-citation>
      </ref>
      <ref id="B66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Batista-Gonzalez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vidal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Criollo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carreño</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages</article-title>
          <source>Front Immunol.</source>
          <year>2020</year>
          <volume>10</volume>
          <fpage>2993</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2019.02993</pub-id>
          <pub-id pub-id-type="pmid">31998297</pub-id>
          <pub-id pub-id-type="pmcid">PMC6966486</pub-id>
        </element-citation>
      </ref>
      <ref id="B67">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walther</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Farese</surname>
              <given-names>RV</given-names>
            </name>
          </person-group>
          <article-title>Lipid droplet biogenesis</article-title>
          <source>Annu Rev Cell Dev Biol.</source>
          <year>2017</year>
          <volume>33</volume>
          <fpage>491</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100616-060608</pub-id>
          <pub-id pub-id-type="pmid">28793795</pub-id>
          <pub-id pub-id-type="pmcid">PMC6986389</pub-id>
        </element-citation>
      </ref>
      <ref id="B68">
        <label>68</label>
        <element-citation publication-type="journal">
		<person-group person-group-type="author">
            <name>
              <surname>Rosenson</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Brewer</surname>
              <given-names>HB Jr</given-names>
            </name>
            <name>
              <surname>Ansell</surname>
              <given-names>BJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dysfunctional HDL and atherosclerotic cardiovascular disease</article-title>
          <source>Nat Rev Cardiol.</source>
          <year>2016</year>
          <volume>13</volume>
          <fpage>48</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1038/nrcardio.2015.124</pub-id>
          <pub-id pub-id-type="pmid">26323267</pub-id>
          <pub-id pub-id-type="pmcid">PMC6245940</pub-id>
        </element-citation>
      </ref>
      <ref id="B69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siegel-Axel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Daub</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Seizer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lindemann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gawaz</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis</article-title>
          <source>Cardiovasc Res.</source>
          <year>2008</year>
          <volume>78</volume>
          <fpage>8</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1093/cvr/cvn015</pub-id>
          <pub-id pub-id-type="pmid">18218686</pub-id>
        </element-citation>
      </ref>
      <ref id="B70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis</article-title>
          <source>Protein Cell.</source>
          <year>2012</year>
          <volume>3</volume>
          <fpage>173</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="doi">10.1007/s13238-012-2025-6</pub-id>
          <pub-id pub-id-type="pmid">22447659</pub-id>
          <pub-id pub-id-type="pmcid">PMC4875426</pub-id>
        </element-citation>
      </ref>
      <ref id="B71">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mclaren</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Ashlin</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Ramji</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy</article-title>
          <source>Prog Lipid Res.</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>331</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1016/j.plipres.2011.04.002</pub-id>
          <pub-id pub-id-type="pmid">21601592</pub-id>
        </element-citation>
      </ref>
      <ref id="B72">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galindo</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yeh</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Razani</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets</article-title>
          <source>Expert Opin Ther Targets.</source>
          <year>2023</year>
          <volume>27</volume>
          <fpage>1231</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1080/14728222.2023.2288272</pub-id>
          <pub-id pub-id-type="pmid">38009300</pub-id>
          <pub-id pub-id-type="pmcid">PMC10843715</pub-id>
        </element-citation>
      </ref>
      <ref id="B73">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Haider</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moly</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Ginsenoside Rb1 protects human vascular smooth muscle cells against resistin-induced oxidative stress and dysfunction</article-title>
          <source>Front Cardiovasc Med.</source>
          <year>2023</year>
          <volume>10</volume>
          <fpage>1164547</fpage>
          <pub-id pub-id-type="doi">10.3389/fcvm.2023.1164547</pub-id>
          <pub-id pub-id-type="pmid">37304947</pub-id>
          <pub-id pub-id-type="pmcid">PMC10248054</pub-id>
        </element-citation>
      </ref>
      <ref id="B74">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Everts</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Amiel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>SC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation</article-title>
          <source>Nat Immunol.</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>323</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.2833</pub-id>
          <pub-id pub-id-type="pmid">24562310</pub-id>
          <pub-id pub-id-type="pmcid">PMC4358322</pub-id>
        </element-citation>
      </ref>
      <ref id="B75">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cader</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Boroviak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>C13orf31 (FAMIN) is a central regulator of immunometabolic function</article-title>
          <source>Nat Immunol.</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>1046</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.3532</pub-id>
          <pub-id pub-id-type="pmid">27478939</pub-id>
          <pub-id pub-id-type="pmcid">PMC6581540</pub-id>
        </element-citation>
      </ref>
      <ref id="B76">
        <label>76</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeon</surname>
              <given-names>TI</given-names>
            </name>
            <name>
              <surname>Osborne</surname>
              <given-names>TF</given-names>
            </name>
          </person-group>
          <article-title>SREBPs: metabolic integrators in physiology and metabolism</article-title>
          <source>Trends in Endocrinol Metab.</source>
          <year>2012</year>
          <volume>23</volume>
          <fpage>65</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tem.2011.10.004</pub-id>
          <pub-id pub-id-type="pmid">22154484</pub-id>
          <pub-id pub-id-type="pmcid">PMC3273665</pub-id>
        </element-citation>
      </ref>
      <ref id="B77">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimano</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology</article-title>
          <source>Nat Rev Endocrinol.</source>
          <year>2017</year>
          <volume>13</volume>
          <fpage>710</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1038/nrendo.2017.91</pub-id>
          <pub-id pub-id-type="pmid">28849786</pub-id>
        </element-citation>
      </ref>
      <ref id="B78">
        <label>78</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guertin</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Wellen</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
          <article-title>Acetyl-CoA metabolism in cancer</article-title>
          <source>Nat Rev Cancer.</source>
          <year>2023</year>
          <volume>23</volume>
          <fpage>156</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1038/s41568-022-00543-5</pub-id>
          <pub-id pub-id-type="pmid">36658431</pub-id>
          <pub-id pub-id-type="pmcid">PMC11137663</pub-id>
        </element-citation>
      </ref>
      <ref id="B79">
        <label>79</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Metallo</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Gameiro</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>EL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia</article-title>
          <source>Nature.</source>
          <year>2011</year>
          <volume>481</volume>
          <fpage>380</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1038/nature10602</pub-id>
          <pub-id pub-id-type="pmid">22101433</pub-id>
          <pub-id pub-id-type="pmcid">PMC3710581</pub-id>
        </element-citation>
      </ref>
      <ref id="B80">
        <label>80</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Phelan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SREBP-1a-stimulated lipid synthesis is required for macrophage phagocytosis downstream of TLR4-directed mTORC1</article-title>
          <source>Proc Natl Acad Sci U S A.</source>
          <year>2018</year>
          <volume>115</volume>
          <fpage>E12228</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1813458115</pub-id>
          <pub-id pub-id-type="pmid">30530672</pub-id>
          <pub-id pub-id-type="pmcid">PMC6310840</pub-id>
        </element-citation>
      </ref>
      <ref id="B81">
        <label>81</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Im</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Yousef</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Blaschitz</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a</article-title>
          <source>Cell Metab.</source>
          <year>2011</year>
          <volume>13</volume>
          <fpage>540</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cmet.2011.04.001</pub-id>
          <pub-id pub-id-type="pmid">21531336</pub-id>
          <pub-id pub-id-type="pmcid">PMC3090630</pub-id>
        </element-citation>
      </ref>
      <ref id="B82">
        <label>82</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Reitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>De Brabander</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs</article-title>
          <source>J Biol Chem.</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>52772</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M410302200</pub-id>
          <pub-id pub-id-type="pmid">15452130</pub-id>
        </element-citation>
      </ref>
      <ref id="B83">
        <label>83</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canfrán-Duque</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rotllan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage-Derived 25-Hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling</article-title>
          <source>Circulation.</source>
          <year>2023</year>
          <volume>147</volume>
          <fpage>388</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.122.059062</pub-id>
          <pub-id pub-id-type="pmid">36416142</pub-id>
          <pub-id pub-id-type="pmcid">PMC9892282</pub-id>
        </element-citation>
      </ref>
      <ref id="B84">
        <label>84</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ran</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Duan</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>7-Dehydrocholesterol dictates ferroptosis sensitivity</article-title>
          <source>Nature.</source>
          <year>2024</year>
          <volume>626</volume>
          <fpage>411</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-023-06983-9</pub-id>
          <pub-id pub-id-type="pmid">38297130</pub-id>
          <pub-id pub-id-type="pmcid">PMC11298758</pub-id>
        </element-citation>
      </ref>
      <ref id="B85">
        <label>85</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeting 7-dehydrocholesterol reductase integrates cholesterol metabolism and IRF3 activation to eliminate infection</article-title>
          <source>Immunity.</source>
          <year>2020</year>
          <volume>52</volume>
          <fpage>109</fpage>
          <lpage>122.e6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2019.11.015</pub-id>
          <pub-id pub-id-type="pmid">31882361</pub-id>
        </element-citation>
      </ref>
      <ref id="B86">
        <label>86</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sánchez-Rodríguez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Spera</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reactive oxygen species in macrophages: sources and targets</article-title>
          <source>Front Immunol.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>734229</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2021.734229</pub-id>
          <pub-id pub-id-type="pmid">34659222</pub-id>
          <pub-id pub-id-type="pmcid">PMC8515906</pub-id>
        </element-citation>
      </ref>
      <ref id="B87">
        <label>87</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Signaling pathways and defense mechanisms of ferroptosis</article-title>
          <source>FEBS J.</source>
          <year>2021</year>
          <volume>289</volume>
          <fpage>7038</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1111/febs.16059</pub-id>
          <pub-id pub-id-type="pmid">34092035</pub-id>
        </element-citation>
      </ref>
      <ref id="B88">
        <label>88</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fei</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeted GSH-exhausting and hydroxyl radical self-producing manganese-silica nanomissiles for MRI guided ferroptotic cancer therapy</article-title>
          <source>Nanoscale.</source>
          <year>2020</year>
          <volume>12</volume>
          <fpage>16738</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1039/d0nr02396e</pub-id>
          <pub-id pub-id-type="pmid">32578659</pub-id>
        </element-citation>
      </ref>
      <ref id="B89">
        <label>89</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chrisnasari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hennebelle</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vincken</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>van Berkel</surname>
              <given-names>WJH</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Bacterial lipoxygenases: Biochemical characteristics, molecular structure and potential applications</article-title>
          <source>Biotechnol Adv.</source>
          <year>2022</year>
          <volume>61</volume>
          <fpage>108046</fpage>
          <pub-id pub-id-type="doi">10.1016/j.biotechadv.2022.108046</pub-id>
          <pub-id pub-id-type="pmid">36202263</pub-id>
        </element-citation>
      </ref>
      <ref id="B90">
        <label>90</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandey</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Flück</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>NADPH P450 oxidoreductase: structure, function, and pathology of diseases</article-title>
          <source>Pharmacol Ther.</source>
          <year>2013</year>
          <volume>138</volume>
          <fpage>229</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.01.010</pub-id>
          <pub-id pub-id-type="pmid">23353702</pub-id>
        </element-citation>
      </ref>
      <ref id="B91">
        <label>91</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rochette</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dogon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rigal</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zeller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cottin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Vergely</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis</article-title>
          <source>Int J Mol Sci.</source>
          <year>2022</year>
          <volume>24</volume>
          <fpage>449</fpage>
          <pub-id pub-id-type="doi">10.3390/ijms24010449</pub-id>
          <pub-id pub-id-type="pmid">36613888</pub-id>
          <pub-id pub-id-type="pmcid">PMC9820499</pub-id>
        </element-citation>
      </ref>
      <ref id="B92">
        <label>92</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XD</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>MQ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The mechanisms of ferroptosis and its role in atherosclerosis</article-title>
          <source>Biomed Pharmacother.</source>
          <year>2024</year>
          <volume>171</volume>
          <fpage>116112</fpage>
          <pub-id pub-id-type="doi">10.1016/j.biopha.2023.116112</pub-id>
          <pub-id pub-id-type="pmid">38171246</pub-id>
        </element-citation>
      </ref>
      <ref id="B93">
        <label>93</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment</article-title>
          <source>Biochim Biophys Acta Rev Cancer.</source>
          <year>2023</year>
          <volume>1878</volume>
          <fpage>188890</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bbcan.2023.188890</pub-id>
          <pub-id pub-id-type="pmid">37001616</pub-id>
        </element-citation>
      </ref>
      <ref id="B94">
        <label>94</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bersuker</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hendricks</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis</article-title>
          <source>Nature.</source>
          <year>2019</year>
          <volume>575</volume>
          <fpage>688</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-019-1705-2</pub-id>
          <pub-id pub-id-type="pmid">31634900</pub-id>
          <pub-id pub-id-type="pmcid">PMC6883167</pub-id>
        </element-citation>
      </ref>
      <ref id="B95">
        <label>95</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doll</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>FSP1 is a glutathione-independent ferroptosis suppressor</article-title>
          <source>Nature.</source>
          <year>2019</year>
          <volume>575</volume>
          <fpage>693</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-019-1707-0</pub-id>
          <pub-id pub-id-type="pmid">31634899</pub-id>
        </element-citation>
      </ref>
      <ref id="B96">
        <label>96</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mishima</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A non-canonical vitamin K cycle is a potent ferroptosis suppressor</article-title>
          <source>Nature.</source>
          <year>2022</year>
          <volume>608</volume>
          <fpage>778</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-022-05022-3</pub-id>
          <pub-id pub-id-type="pmid">35922516</pub-id>
          <pub-id pub-id-type="pmcid">PMC9402432</pub-id>
        </element-citation>
      </ref>
      <ref id="B97">
        <label>97</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kraft</surname>
              <given-names>VAN</given-names>
            </name>
            <name>
              <surname>Bezjian</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Pfeiffer</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling</article-title>
          <source>ACS Cent Sci.</source>
          <year>2019</year>
          <volume>6</volume>
          <fpage>41</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1021/acscentsci.9b01063</pub-id>
          <pub-id pub-id-type="pmid">31989025</pub-id>
          <pub-id pub-id-type="pmcid">PMC6978838</pub-id>
        </element-citation>
      </ref>
      <ref id="B98">
        <label>98</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Author Correction: DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer</article-title>
          <source>Nature.</source>
          <year>2021</year>
          <volume>596</volume>
          <fpage>E13</fpage>
          <pub-id pub-id-type="doi">10.1038/s41586-021-03820-9</pub-id>
          <pub-id pub-id-type="pmid">34341547</pub-id>
        </element-citation>
      </ref>
      <ref id="B99">
        <label>99</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zandkarimi</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones</article-title>
          <source>Cell.</source>
          <year>2023</year>
          <volume>186</volume>
          <fpage>2748</fpage>
          <lpage>64.e22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2023.05.003</pub-id>
          <pub-id pub-id-type="pmid">37267948</pub-id>
          <pub-id pub-id-type="pmcid">PMC10330611</pub-id>
        </element-citation>
      </ref>
      <ref id="B100">
        <label>100</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4</article-title>
          <source>Nat Commun.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>3644</fpage>
          <pub-id pub-id-type="doi">10.1038/s41467-021-23902-6</pub-id>
          <pub-id pub-id-type="pmid">34131139</pub-id>
          <pub-id pub-id-type="pmcid">PMC8206155</pub-id>
        </element-citation>
      </ref>
      <ref id="B101">
        <label>101</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Heme oxygenase-1 modulates ferroptosis by fine-tuning levels of intracellular iron and reactive oxygen species of macrophages in response to <italic>Bacillus Calmette-Guerin</italic> infection</article-title>
          <source>Front Cell Infect Microbiol.</source>
          <year>2022</year>
          <volume>12</volume>
          <fpage>1004148</fpage>
          <pub-id pub-id-type="doi">10.3389/fcimb.2022.1004148</pub-id>
          <pub-id pub-id-type="pmid">36211962</pub-id>
          <pub-id pub-id-type="pmcid">PMC9539760</pub-id>
        </element-citation>
      </ref>
      <ref id="B102">
        <label>102</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nairz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Theurl</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Swirski</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>“Pumping iron” - how macrophages handle iron at the systemic, microenvironmental, and cellular levels</article-title>
          <source>Pflugers Arch - Eur J Physiol.</source>
          <year>2017</year>
          <volume>469</volume>
          <fpage>397</fpage>
          <lpage>418</lpage>
          <pub-id pub-id-type="doi">10.1007/s00424-017-1944-8</pub-id>
          <pub-id pub-id-type="pmid">28251312</pub-id>
          <pub-id pub-id-type="pmcid">PMC5362662</pub-id>
        </element-citation>
      </ref>
      <ref id="B103">
        <label>103</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Das</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transferrin receptor 1-mediated iron uptake regulates bone mass in mice via osteoclast mitochondria and cytoskeleton</article-title>
          <source>ELife.</source>
          <year>2022</year>
          <volume>11</volume>
          <fpage>e73539</fpage>
          <pub-id pub-id-type="doi">10.7554/eLife.73539</pub-id>
          <pub-id pub-id-type="pmid">35758636</pub-id>
          <pub-id pub-id-type="pmcid">PMC9352353</pub-id>
        </element-citation>
      </ref>
      <ref id="B104">
        <label>104</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koleini</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Geier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ardehali</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Ironing out mechanisms of iron homeostasis and disorders of iron deficiency</article-title>
          <source>J Clin Invest.</source>
          <year>2021</year>
          <volume>131</volume>
          <fpage>e148671</fpage>
          <pub-id pub-id-type="doi">10.1172/JCI148671</pub-id>
          <pub-id pub-id-type="pmid">34060484</pub-id>
          <pub-id pub-id-type="pmcid">PMC8159681</pub-id>
        </element-citation>
      </ref>
      <ref id="B105">
        <label>105</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation</article-title>
          <source>Blood.</source>
          <year>2021</year>
          <volume>138</volume>
          <fpage>689</fpage>
          <lpage>705</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.2020008986</pub-id>
          <pub-id pub-id-type="pmid">33895792</pub-id>
          <pub-id pub-id-type="pmcid">PMC8394904</pub-id>
        </element-citation>
      </ref>
      <ref id="B106">
        <label>106</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saad</surname>
              <given-names>HKM</given-names>
            </name>
            <name>
              <surname>Abd Rahman</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Ab Ghani</surname>
              <given-names>AS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-thalassemia patients</article-title>
          <source>Biomedicines.</source>
          <year>2022</year>
          <volume>10</volume>
          <fpage>189</fpage>
          <pub-id pub-id-type="doi">10.3390/biomedicines10010189</pub-id>
          <pub-id pub-id-type="pmid">35052868</pub-id>
          <pub-id pub-id-type="pmcid">PMC8773737</pub-id>
        </element-citation>
      </ref>
      <ref id="B107">
        <label>107</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mleczko-Sanecka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Silvestri</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Cell-type-specific insights into iron regulatory processes</article-title>
          <source>Am J Hematol.</source>
          <year>2020</year>
          <volume>96</volume>
          <fpage>110</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.26001</pub-id>
          <pub-id pub-id-type="pmid">32945012</pub-id>
        </element-citation>
      </ref>
      <ref id="B108">
        <label>108</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Molecular, physiological and clinical aspects of the iron storage protein ferritin</article-title>
          <source>Vet J.</source>
          <year>2008</year>
          <volume>178</volume>
          <fpage>191</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tvjl.2007.07.006</pub-id>
          <pub-id pub-id-type="pmid">17764995</pub-id>
        </element-citation>
      </ref>
      <ref id="B109">
        <label>109</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mancias</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Gygi</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Kimmelman</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy</article-title>
          <source>Nature.</source>
          <year>2014</year>
          <volume>509</volume>
          <fpage>105</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1038/nature13148</pub-id>
          <pub-id pub-id-type="pmid">24695223</pub-id>
          <pub-id pub-id-type="pmcid">PMC4180099</pub-id>
        </element-citation>
      </ref>
      <ref id="B110">
        <label>110</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohshima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sakamaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mizushima</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>NCOA4 drives ferritin phase separation to facilitate macroferritinophagy and microferritinophagy</article-title>
          <source>J Cell Biol.</source>
          <year>2022</year>
		  <volume>221</volume>
          <fpage>e202203102</fpage> 
          <pub-id pub-id-type="doi">10.1083/jcb.202203102</pub-id>
          <pub-id pub-id-type="pmid">36066504</pub-id>
          <pub-id pub-id-type="pmcid">PMC9452830</pub-id>
        </element-citation>
      </ref>
      <ref id="B111">
        <label>111</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xie</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Fefelova</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pamarthi</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Gwathmey</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of ferroptosis and relevance to cardiovascular disease</article-title>
          <source>Cells.</source>
          <year>2022</year>
          <volume>11</volume>
          <fpage>2726</fpage>
          <pub-id pub-id-type="doi">10.3390/cells11172726</pub-id>
          <pub-id pub-id-type="pmid">36078133</pub-id>
          <pub-id pub-id-type="pmcid">PMC9454912</pub-id>
        </element-citation>
      </ref>
      <ref id="B112">
        <label>112</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marques</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Leal</surname>
              <given-names>MAS</given-names>
            </name>
            <name>
              <surname>Mageski</surname>
              <given-names>JGA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chronic iron overload intensifies atherosclerosis in apolipoprotein E deficient mice: Role of oxidative stress and endothelial dysfunction</article-title>
          <source>Life Sci.</source>
          <year>2019</year>
          <volume>233</volume>
          <fpage>116702</fpage>
          <pub-id pub-id-type="doi">10.1016/j.lfs.2019.116702</pub-id>
          <pub-id pub-id-type="pmid">31356905</pub-id>
        </element-citation>
      </ref>
      <ref id="B113">
        <label>113</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietrangelo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment</article-title>
          <source>Gastroenterology.</source>
          <year>2010</year>
          <volume>139</volume>
          <fpage>393</fpage>
          <lpage>408.e1</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2010.06.013</pub-id>
          <pub-id pub-id-type="pmid">20542038</pub-id>
        </element-citation>
      </ref>
      <ref id="B114">
        <label>114</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vinchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Porto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Simmelbauer</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction</article-title>
          <source>Eur Heart J.</source>
          <year>2020</year>
          <volume>41</volume>
          <fpage>2681</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehz112</pub-id>
          <pub-id pub-id-type="pmid">30903157</pub-id>
        </element-citation>
      </ref>
      <ref id="B115">
        <label>115</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Iron-load exacerbates the severity of atherosclerosis via inducing inflammation and enhancing the glycolysis in macrophages</article-title>
          <source>J Cell Physiol.</source>
          <year>2019</year>
          <volume>234</volume>
          <fpage>18792</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.28518</pub-id>
          <pub-id pub-id-type="pmid">30927265</pub-id>
        </element-citation>
      </ref>
      <ref id="B116">
        <label>116</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyle</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Harrington</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Piper</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype</article-title>
          <source>Am J Pathol.</source>
          <year>2009</year>
          <volume>174</volume>
          <fpage>1097</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="doi">10.2353/ajpath.2009.080431</pub-id>
          <pub-id pub-id-type="pmid">19234137</pub-id>
          <pub-id pub-id-type="pmcid">PMC2665768</pub-id>
        </element-citation>
      </ref>
      <ref id="B117">
        <label>117</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersen</surname>
              <given-names>CBF</given-names>
            </name>
            <name>
              <surname>Stødkilde</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sæderup</surname>
              <given-names>KL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Haptoglobin</article-title>
          <source>Antioxid Redox Signal.</source>
          <year>2017</year>
          <volume>26</volume>
          <fpage>814</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1089/ars.2016.6793</pub-id>
          <pub-id pub-id-type="pmid">27650279</pub-id>
        </element-citation>
      </ref>
      <ref id="B118">
        <label>118</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Habib</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis</article-title>
          <source>Front Pharmacol.</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>195</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2014.00195</pub-id>
          <pub-id pub-id-type="pmid">25221512</pub-id>
          <pub-id pub-id-type="pmcid">PMC4145350</pub-id>
        </element-citation>
      </ref>
      <ref id="B119">
        <label>119</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buehler</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vallelian</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification</article-title>
          <source>Blood.</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>2578</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-08-174466</pub-id>
          <pub-id pub-id-type="pmid">19131549</pub-id>
        </element-citation>
      </ref>
      <ref id="B120">
        <label>120</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Potor</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hendrik</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Patsalos</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oxidation of hemoglobin drives a proatherogenic polarization of macrophages in human atherosclerosis</article-title>
          <source>Antioxid Redox Signal.</source>
          <year>2021</year>
          <volume>35</volume>
          <fpage>917</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1089/ars.2020.8234</pub-id>
          <pub-id pub-id-type="pmid">34269613</pub-id>
          <pub-id pub-id-type="pmcid">PMC8905252</pub-id>
        </element-citation>
      </ref>
      <ref id="B121">
        <label>121</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ross</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Devitt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Macrophages: the good, the bad, and the gluttony</article-title>
          <source>Front Immunol.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>708186</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2021.708186</pub-id>
          <pub-id pub-id-type="pmid">34456917</pub-id>
          <pub-id pub-id-type="pmcid">PMC8397413</pub-id>
        </element-citation>
      </ref>
      <ref id="B122">
        <label>122</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ACSL4 promotes ferroptosis and M1 macrophage polarization to regulate the tumorigenesis of nasopharyngeal carcinoma</article-title>
          <source>Int Immunopharmacol.</source>
          <year>2023</year>
          <volume>122</volume>
          <fpage>110629</fpage>
          <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110629</pub-id>
          <pub-id pub-id-type="pmid">37451020</pub-id>
        </element-citation>
      </ref>
      <ref id="B123">
        <label>123</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xuan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Hmox1 is identified as a ferroptosis hub gene and associated with the M1 type microglia/macrophage polarization in spinal cord injury: bioinformatics and experimental validation</article-title>
          <source>Mol Neurobiol.</source>
          <year>2023</year>
          <volume>60</volume>
          <fpage>7151</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1007/s12035-023-03543-0</pub-id>
          <pub-id pub-id-type="pmid">37532969</pub-id>
        </element-citation>
      </ref>
      <ref id="B124">
        <label>124</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages</article-title>
          <source>J Exp Clin Cancer Res.</source>
          <year>2023</year>
          <volume>42</volume>
          <fpage>286</fpage>
          <pub-id pub-id-type="doi">10.1186/s13046-023-02865-0</pub-id>
          <pub-id pub-id-type="pmid">37891677</pub-id>
          <pub-id pub-id-type="pmcid">PMC10612308</pub-id>
        </element-citation>
      </ref>
      <ref id="B125">
        <label>125</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dai</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein</article-title>
          <source>Autophagy.</source>
          <year>2020</year>
          <volume>16</volume>
          <fpage>2069</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1080/15548627.2020.1714209</pub-id>
          <pub-id pub-id-type="pmid">31920150</pub-id>
          <pub-id pub-id-type="pmcid">PMC7595620</pub-id>
        </element-citation>
      </ref>
      <ref id="B126">
        <label>126</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>The role of macrophage iron overload and ferroptosis in atherosclerosis</article-title>
          <source>Biomolecules.</source>
          <year>2022</year>
          <volume>12</volume>
          <fpage>1702</fpage>
          <pub-id pub-id-type="doi">10.3390/biom12111702</pub-id>
          <pub-id pub-id-type="pmid">36421722</pub-id>
          <pub-id pub-id-type="pmcid">PMC9688033</pub-id>
        </element-citation>
      </ref>
      <ref id="B127">
        <label>127</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bäck</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yurdagul</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tabas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Öörni</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kovanen</surname>
              <given-names>PT</given-names>
            </name>
          </person-group>
          <article-title>Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities</article-title>
          <source>Nat Rev Cardiol.</source>
          <year>2019</year>
          <fpage>16:389</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1038/s41569-019-0169-2</pub-id>
          <pub-id pub-id-type="pmid">30846875</pub-id>
          <pub-id pub-id-type="pmcid">PMC6727648</pub-id>
        </element-citation>
      </ref>
      <ref id="B128">
        <label>128</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage iron retention aggravates atherosclerosis: Evidence for the role of autocrine formation of hepcidin in plaque macrophages</article-title>
          <source>Biochim Biophys Acta Mol Cell Biol Lipids.</source>
          <year>2020</year>
          <volume>1865</volume>
          <fpage>158531</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bbalip.2019.158531</pub-id>
          <pub-id pub-id-type="pmid">31666189</pub-id>
        </element-citation>
      </ref>
      <ref id="B129">
        <label>129</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neels</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Gollentz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chinetti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Macrophage death in atherosclerosis: potential role in calcification</article-title>
          <source>Front Immunol.</source>
          <year>2023</year>
          <volume>14</volume>
          <fpage>1215612</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2023.1215612</pub-id>
          <pub-id pub-id-type="pmid">37469518</pub-id>
          <pub-id pub-id-type="pmcid">PMC10352763</pub-id>
        </element-citation>
      </ref>
      <ref id="B130">
        <label>130</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Amante</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Chhoy</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prominin2 drives ferroptosis resistance by stimulating iron export</article-title>
          <source>Dev Cell.</source>
          <year>2019</year>
          <volume>51</volume>
          <fpage>575</fpage>
          <lpage>86.e4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.devcel.2019.10.007</pub-id>
          <pub-id pub-id-type="pmid">31735663</pub-id>
          <pub-id pub-id-type="pmcid">PMC8316835</pub-id>
        </element-citation>
      </ref>
      <ref id="B131">
        <label>131</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yaker</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tebani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lesueur</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extracellular vesicles from LPS-treated macrophages aggravate smooth muscle cell calcification by propagating inflammation and oxidative stress</article-title>
          <source>Front Cell Dev Biol.</source>
          <year>2022</year>
          <volume>10</volume>
          <fpage>823450</fpage>
          <pub-id pub-id-type="doi">10.3389/fcell.2022.823450</pub-id>
          <pub-id pub-id-type="pmid">35356285</pub-id>
          <pub-id pub-id-type="pmcid">PMC8959646</pub-id>
        </element-citation>
      </ref>
      <ref id="B132">
        <label>132</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawakami</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Katsuki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Travers</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>S100A9-RAGE axis accelerates formation of macrophage-mediated extracellular vesicle microcalcification in diabetes mellitus</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2020</year>
          <volume>40</volume>
          <fpage>1838</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.314087</pub-id>
          <pub-id pub-id-type="pmid">32460581</pub-id>
          <pub-id pub-id-type="pmcid">PMC7377960</pub-id>
        </element-citation>
      </ref>
      <ref id="B133">
        <label>133</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerins</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ooi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The roles of NRF2 in modulating cellular iron homeostasis</article-title>
          <source>Antioxid Redox Signal.</source>
          <year>2018</year>
          <volume>29</volume>
          <fpage>1756</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1089/ars.2017.7176</pub-id>
          <pub-id pub-id-type="pmid">28793787</pub-id>
          <pub-id pub-id-type="pmcid">PMC6208163</pub-id>
        </element-citation>
      </ref>
      <ref id="B134">
        <label>134</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kobayashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okawa</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</article-title>
          <source>Mol Cell Biol.</source>
          <year>2023</year>
          <volume>24</volume>
          <fpage>7130</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.24.16.7130-7139.2004</pub-id>
          <pub-id pub-id-type="pmid">15282312</pub-id>
          <pub-id pub-id-type="pmcid">PMC479737</pub-id>
        </element-citation>
      </ref>
      <ref id="B135">
        <label>135</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>The Nrf2 antioxidant defense system in intervertebral disc degeneration: Molecular insights</article-title>
          <source>Exp Mol Med.</source>
          <year>2022</year>
          <volume>54</volume>
          <fpage>1067</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1038/s12276-022-00829-6</pub-id>
          <pub-id pub-id-type="pmid">35978054</pub-id>
          <pub-id pub-id-type="pmcid">PMC9440120</pub-id>
        </element-citation>
      </ref>
      <ref id="B136">
        <label>136</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ren</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Paeoniflorin alleviates AngII-induced cardiac hypertrophy in H9c2 cells by regulating oxidative stress and Nrf2 signaling pathway</article-title>
          <source>Biomed Pharmacother.</source>
          <year>2023</year>
          <volume>165</volume>
          <fpage>115253</fpage>
          <pub-id pub-id-type="doi">10.1016/j.biopha.2023.115253</pub-id>
          <pub-id pub-id-type="pmid">37542855</pub-id>
        </element-citation>
      </ref>
      <ref id="B137">
        <label>137</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gutiérrez-Cuevas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Galicia-Moreno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Monroy-Ramírez</surname>
              <given-names>HC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The role of NRF2 in obesity-associated cardiovascular risk factors</article-title>
          <source>Antioxidants.</source>
          <year>2022</year>
          <volume>11</volume>
          <fpage>235</fpage>
          <pub-id pub-id-type="doi">10.3390/antiox11020235</pub-id>
          <pub-id pub-id-type="pmid">35204118</pub-id>
          <pub-id pub-id-type="pmcid">PMC8868420</pub-id>
        </element-citation>
      </ref>
      <ref id="B138">
        <label>138</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>MCL attenuates atherosclerosis by suppressing macrophage ferroptosis via targeting KEAP1/NRF2 interaction</article-title>
          <source>Redox Biol.</source>
          <year>2024</year>
          <volume>69</volume>
          <fpage>102987</fpage>
          <pub-id pub-id-type="doi">10.1016/j.redox.2023.102987</pub-id>
          <pub-id pub-id-type="pmid">38100883</pub-id>
          <pub-id pub-id-type="pmcid">PMC10761782</pub-id>
        </element-citation>
      </ref>
      <ref id="B139">
        <label>139</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Ambient fine particulate matter aggravates atherosclerosis in apolipoprotein E knockout mice by iron overload via the hepcidin-ferroportin axis</article-title>
          <source>Life Sci.</source>
          <year>2021</year>
          <volume>264</volume>
          <fpage>118715</fpage>
          <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118715</pub-id>
          <pub-id pub-id-type="pmid">33160991</pub-id>
        </element-citation>
      </ref>
      <ref id="B140">
        <label>140</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cigarette tar mediates macrophage ferroptosis in atherosclerosis through the hepcidin/FPN/SLC7A11 signaling pathway</article-title>
          <source>Free Radic Biol Med.</source>
          <year>2023</year>
          <volume>201</volume>
          <fpage>76</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.03.006</pub-id>
          <pub-id pub-id-type="pmid">36933812</pub-id>
        </element-citation>
      </ref>
      <ref id="B141">
        <label>141</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemeth</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ganz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Hepcidin and iron in health and disease</article-title>
          <source>Annu Rev Med.</source>
          <year>2023</year>
          <volume>74</volume>
          <fpage>261</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-med-043021-032816</pub-id>
          <pub-id pub-id-type="pmid">35905974</pub-id>
          <pub-id pub-id-type="pmcid">PMC9943683</pub-id>
        </element-citation>
      </ref>
      <ref id="B142">
        <label>142</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Billesbølle</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Azumaya</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Kretsch</surname>
              <given-names>RC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms</article-title>
          <source>Nature.</source>
          <year>2020</year>
          <volume>586</volume>
          <fpage>807</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-020-2668-z</pub-id>
          <pub-id pub-id-type="pmid">32814342</pub-id>
          <pub-id pub-id-type="pmcid">PMC7906036</pub-id>
        </element-citation>
      </ref>
      <ref id="B143">
        <label>143</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camaschella</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silvestri</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Iron metabolism and iron disorders revisited in the hepcidin era</article-title>
          <source>Haematologica.</source>
          <year>2020</year>
          <volume>105</volume>
          <fpage>260</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2019.232124</pub-id>
          <pub-id pub-id-type="pmid">31949017</pub-id>
          <pub-id pub-id-type="pmcid">PMC7012465</pub-id>
        </element-citation>
      </ref>
      <ref id="B144">
        <label>144</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>ZM</given-names>
            </name>
          </person-group>
          <article-title>Iron metabolism and atherosclerosis</article-title>
          <source>Trends in Endocrinol Metab.</source>
          <year>2023</year>
          <volume>34</volume>
          <fpage>404</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tem.2023.04.003</pub-id>
          <pub-id pub-id-type="pmid">37210298</pub-id>
        </element-citation>
      </ref>
      <ref id="B145">
        <label>145</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malhotra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wunderer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>HJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepcidin Deficiency Protects Against Atherosclerosis</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2019</year>
          <volume>39</volume>
          <fpage>178</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.312215</pub-id>
          <pub-id pub-id-type="pmid">30587002</pub-id>
          <pub-id pub-id-type="pmcid">PMC6344241</pub-id>
        </element-citation>
      </ref>
      <ref id="B146">
        <label>146</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galesloot</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Holewijn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kiemeney</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>de Graaf</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vermeulen</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Swinkels</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2014</year>
          <volume>34</volume>
          <fpage>446</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.113.302381</pub-id>
          <pub-id pub-id-type="pmid">24334869</pub-id>
        </element-citation>
      </ref>
      <ref id="B147">
        <label>147</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galesloot</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Janss</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Iron and hepcidin as risk factors in atherosclerosis: what do the genes say? <italic>BMC Genet.</italic> 2015;16:79</article-title>
          <pub-id pub-id-type="doi">10.1186/s12863-015-0246-4</pub-id>
          <pub-id pub-id-type="pmid">26159428</pub-id>
          <pub-id pub-id-type="pmcid">PMC4498499</pub-id>
        </element-citation>
      </ref>
      <ref id="B148">
        <label>148</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sindrilaru</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wieschalka</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice</article-title>
          <source>J Clin Invest.</source>
          <year>2011</year>
          <volume>121</volume>
          <fpage>985</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI44490</pub-id>
          <pub-id pub-id-type="pmid">21317534</pub-id>
          <pub-id pub-id-type="pmcid">PMC3049372</pub-id>
        </element-citation>
      </ref>
      <ref id="B149">
        <label>149</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zanganeh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hutter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Spitler</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues</article-title>
          <source>Nat Nanotechnol.</source>
          <year>2016</year>
          <volume>11</volume>
          <fpage>986</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1038/nnano.2016.168</pub-id>
          <pub-id pub-id-type="pmid">27668795</pub-id>
          <pub-id pub-id-type="pmcid">PMC5198777</pub-id>
        </element-citation>
      </ref>
      <ref id="B150">
        <label>150</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saeed</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Polavarapu</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis</article-title>
          <source>Arterioscler Thromb Vasc Biol.</source>
          <year>2012</year>
          <volume>32</volume>
          <fpage>299</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.240101</pub-id>
          <pub-id pub-id-type="pmid">22095982</pub-id>
          <pub-id pub-id-type="pmcid">PMC3262074</pub-id>
        </element-citation>
      </ref>
      <ref id="B151">
        <label>151</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruiswijk</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Labuschagne</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Vousden</surname>
              <given-names>KH</given-names>
            </name>
          </person-group>
          <article-title>p53 in survival, death and metabolic health: a lifeguard with a licence to kill</article-title>
          <source>Nat Rev Mol Cell Biol.</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>393</fpage>
          <lpage>405</lpage>
          <pub-id pub-id-type="doi">10.1038/nrm4007</pub-id>
          <pub-id pub-id-type="pmid">26122615</pub-id>
        </element-citation>
      </ref>
      <ref id="B152">
        <label>152</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Ferroptosis and the bidirectional regulatory factor p53</article-title>
          <source>Cell Death Discov.</source>
          <year>2023</year>
          <volume>9</volume>
          <fpage>197</fpage>
          <pub-id pub-id-type="doi">10.1038/s41420-023-01517-8</pub-id>
          <pub-id pub-id-type="pmid">37386007</pub-id>
          <pub-id pub-id-type="pmcid">PMC10310766</pub-id>
        </element-citation>
      </ref>
      <ref id="B153">
        <label>153</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway</article-title>
          <source>Cell Death Dis.</source>
          <year>2022</year>
          <volume>13</volume>
          <fpage>530</fpage>
          <pub-id pub-id-type="doi">10.1038/s41419-022-04971-x</pub-id>
          <pub-id pub-id-type="pmid">35668064</pub-id>
          <pub-id pub-id-type="pmcid">PMC9169029</pub-id>
        </element-citation>
      </ref>
      <ref id="B154">
        <label>154</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Activation of <italic>SAT1</italic> engages polyamine metabolism with p53-mediated ferroptotic responses</article-title>
          <source>Proc Natl Acad Sci U S A.</source>
          <year>2016</year>
          <volume>113</volume>
          <fpage>E6806</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1607152113</pub-id>
          <pub-id pub-id-type="pmid">27698118</pub-id>
          <pub-id pub-id-type="pmcid">PMC5098629</pub-id>
        </element-citation>
      </ref>
      <ref id="B155">
        <label>155</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tarangelo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Magtanong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bieging-Rolett</surname>
              <given-names>KT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>p53 suppresses metabolic stress-induced ferroptosis in cancer cells</article-title>
          <source>Cell Rep.</source>
          <year>2018</year>
          <volume>22</volume>
          <fpage>569</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.077</pub-id>
          <pub-id pub-id-type="pmid">29346757</pub-id>
          <pub-id pub-id-type="pmcid">PMC5791910</pub-id>
        </element-citation>
      </ref>
      <ref id="B156">
        <label>156</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mercer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Figg</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stoneman</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Braganza</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice</article-title>
          <source>Circ Res.</source>
          <year>2005</year>
          <volume>96</volume>
          <fpage>667</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1161/01.RES.0000161069.15577.ca</pub-id>
          <pub-id pub-id-type="pmid">15746445</pub-id>
        </element-citation>
      </ref>
      <ref id="B157">
        <label>157</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Que</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway</article-title>
          <source>Cancer Med.</source>
          <year>2018</year>
          <volume>7</volume>
          <fpage>4012</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1002/cam4.1670</pub-id>
          <pub-id pub-id-type="pmid">29989329</pub-id>
          <pub-id pub-id-type="pmcid">PMC6089144</pub-id>
        </element-citation>
      </ref>
      <ref id="B158">
        <label>158</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giovannini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Varì</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Scazzocchio</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>OxLDL induced p53-dependent apoptosis by activating p38MAPK and PKCδ signaling pathways in J774A.1 macrophage cells</article-title>
          <source>J Mol Cell Biol.</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>316</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1093/jmcb/mjr019</pub-id>
          <pub-id pub-id-type="pmid">21920989</pub-id>
        </element-citation>
      </ref>
      <ref id="B159">
        <label>159</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Minikes</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling</article-title>
          <source>Nature.</source>
          <year>2019</year>
          <volume>572</volume>
          <fpage>402</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-019-1426-6</pub-id>
          <pub-id pub-id-type="pmid">31341276</pub-id>
          <pub-id pub-id-type="pmcid">PMC6697195</pub-id>
        </element-citation>
      </ref>
      <ref id="B160">
        <label>160</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Autophagy inhibition and ferroptosis activation during atherosclerosis: hypoxia-inducible factor 1α inhibitor PX-478 alleviates atherosclerosis by inducing autophagy and suppressing ferroptosis in macrophages</article-title>
          <source>Biomed Pharmacother.</source>
          <year>2023</year>
          <volume>161</volume>
          <fpage>114333</fpage>
          <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114333</pub-id>
          <pub-id pub-id-type="pmid">36948130</pub-id>
        </element-citation>
      </ref>
      <ref id="B161">
        <label>161</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Palte</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Deik</surname>
              <given-names>AA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis</article-title>
          <source>Nat Commun.</source>
          <year>2019</year>
          <volume>10</volume>
          <fpage>1617</fpage>
          <pub-id pub-id-type="doi">10.1038/s41467-019-09277-9</pub-id>
          <pub-id pub-id-type="pmid">30962421</pub-id>
          <pub-id pub-id-type="pmcid">PMC6453886</pub-id>
        </element-citation>
      </ref>
      <ref id="B162">
        <label>162</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Metformin suppresses foam cell formation, inflammation and ferroptosis via the AMPK/ERK signaling pathway in ox-LDL-induced THP-1 monocytes</article-title>
          <source>Exp Ther Med.</source>
          <year>2022</year>
          <volume>24</volume>
          <fpage>636</fpage>
          <pub-id pub-id-type="doi">10.3892/etm.2022.11573</pub-id>
          <pub-id pub-id-type="pmid">36160906</pub-id>
          <pub-id pub-id-type="pmcid">PMC9468789</pub-id>
        </element-citation>
      </ref>
      <ref id="B163">
        <label>163</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zandkarimi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Energy-stress-mediated AMPK activation inhibits ferroptosis</article-title>
          <source>Nat Cell Biol.</source>
          <year>2020</year>
          <volume>22</volume>
          <fpage>225</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1038/s41556-020-0461-8</pub-id>
          <pub-id pub-id-type="pmid">32029897</pub-id>
          <pub-id pub-id-type="pmcid">PMC7008777</pub-id>
        </element-citation>
      </ref>
      <ref id="B164">
        <label>164</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Buring</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Badimon</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atherosclerosis</article-title>
          <source>Nat Rev Dis Primers.</source>
          <year>2019</year>
          <volume>5</volume>
          <fpage>56</fpage>
          <pub-id pub-id-type="doi">10.1038/s41572-019-0106-z</pub-id>
          <pub-id pub-id-type="pmid">31420554</pub-id>
        </element-citation>
      </ref>
      <ref id="B165">
        <label>165</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hou</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>hUC-MSC-EV-miR-24 enhances the protective effect of dexmedetomidine preconditioning against myocardial ischemia-reperfusion injury through the KEAP1/Nrf2/HO-1 signaling</article-title>
          <source>Drug Deliv Transl Res.</source>
          <year>2023</year>
          <volume>14</volume>
          <fpage>143</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1007/s13346-023-01388-7</pub-id>
          <pub-id pub-id-type="pmid">37540334</pub-id>
        </element-citation>
      </ref>
      <ref id="B166">
        <label>166</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dexmedetomidine preconditioning alleviated murine liver ischemia and reperfusion injury by promoting macrophage M2 activation via PPARγ/STAT3 signaling</article-title>
          <source>Int Immunopharmacol.</source>
          <year>2020</year>
          <volume>82</volume>
          <fpage>106363</fpage>
          <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106363</pub-id>
          <pub-id pub-id-type="pmid">32145512</pub-id>
        </element-citation>
      </ref>
      <ref id="B167">
        <label>167</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dexmedetomidine alleviates ferroptosis following hepatic ischemia-reperfusion injury by upregulating Nrf2/GPx4-dependent antioxidant responses</article-title>
          <source>Biomed Pharmacother.</source>
          <year>2023</year>
          <volume>169</volume>
          <fpage>115915</fpage>
          <pub-id pub-id-type="doi">10.1016/j.biopha.2023.115915</pub-id>
          <pub-id pub-id-type="pmid">38000361</pub-id>
        </element-citation>
      </ref>
      <ref id="B168">
        <label>168</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mills</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Prag</surname>
              <given-names>HA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1</article-title>
          <source>Nature.</source>
          <year>2018</year>
          <volume>556</volume>
          <fpage>113</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1038/nature25986</pub-id>
          <pub-id pub-id-type="pmid">29590092</pub-id>
          <pub-id pub-id-type="pmcid">PMC6047741</pub-id>
        </element-citation>
      </ref>
      <ref id="B169">
        <label>169</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Frieler</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Itaconate suppresses atherosclerosis by activating a Nrf2-dependent antiinflammatory response in macrophages in mice</article-title>
          <source>J Clin Invest.</source>
          <year>2023</year>
          <volume>134</volume>
          <fpage>e173034</fpage>
          <pub-id pub-id-type="doi">10.1172/JCI173034</pub-id>
          <pub-id pub-id-type="pmid">38085578</pub-id>
          <pub-id pub-id-type="pmcid">PMC10849764</pub-id>
        </element-citation>
      </ref>
      <ref id="B170">
        <label>170</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Itaconate inhibits ferroptosis of macrophage via Nrf2 pathways against sepsis-induced acute lung injury</article-title>
          <source>Cell Death Discov.</source>
          <year>2022</year>
          <volume>8</volume>
          <fpage>43</fpage>
          <pub-id pub-id-type="doi">10.1038/s41420-021-00807-3</pub-id>
          <pub-id pub-id-type="pmid">35110526</pub-id>
          <pub-id pub-id-type="pmcid">PMC8810876</pub-id>
        </element-citation>
      </ref>
      <ref id="B171">
        <label>171</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Uridine alleviates sepsis-induced acute lung injury by inhibiting ferroptosis of macrophage</article-title>
          <source>Int J Mol Sci.</source>
          <year>2023</year>
          <volume>24</volume>
          <fpage>5093</fpage>
          <pub-id pub-id-type="doi">10.3390/ijms24065093</pub-id>
          <pub-id pub-id-type="pmid">36982166</pub-id>
          <pub-id pub-id-type="pmcid">PMC10049139</pub-id>
        </element-citation>
      </ref>
      <ref id="B172">
        <label>172</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amaral</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Namasivayam</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A major role for ferroptosis in <italic>Mycobacterium tuberculosis</italic>-induced cell death and tissue necrosis</article-title>
          <source>J Exp Med.</source>
          <year>2019</year>
          <volume>216</volume>
          <fpage>556</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20181776</pub-id>
          <pub-id pub-id-type="pmid">30787033</pub-id>
          <pub-id pub-id-type="pmcid">PMC6400546</pub-id>
        </element-citation>
      </ref>
      <ref id="B173">
        <label>173</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lachowicz</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Pichiri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Piludu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thymosin β4 Is an endogenous iron chelator and molecular switcher of ferroptosis</article-title>
          <source>Int J Mol Sci.</source>
          <year>2022</year>
          <volume>23</volume>
          <fpage>551</fpage>
          <pub-id pub-id-type="doi">10.3390/ijms23010551</pub-id>
          <pub-id pub-id-type="pmid">35008976</pub-id>
          <pub-id pub-id-type="pmcid">PMC8745404</pub-id>
        </element-citation>
      </ref>
      <ref id="B174">
        <label>174</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4</article-title>
          <source>Eur J Pharmacol.</source>
          <year>2021</year>
          <volume>908</volume>
          <fpage>174351</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174351</pub-id>
          <pub-id pub-id-type="pmid">34280397</pub-id>
        </element-citation>
      </ref>
      <ref id="B175">
        <label>175</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Semaphorin 5A suppresses ferroptosis through activation of PI3K-AKT-mTOR signaling in rheumatoid arthritis</article-title>
          <source>Cell Death Dis.</source>
          <year>2022</year>
          <volume>13</volume>
          <fpage>608</fpage>
          <pub-id pub-id-type="doi">10.1038/s41419-022-05065-4</pub-id>
          <pub-id pub-id-type="pmid">35835748</pub-id>
          <pub-id pub-id-type="pmcid">PMC9283415</pub-id>
        </element-citation>
      </ref>
      <ref id="B176">
        <label>176</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Weng</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Demystifying traditional herbal medicine with modern approach</article-title>
          <source>Nature Plants.</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>17109</fpage>
          <pub-id pub-id-type="doi">10.1038/nplants.2017.109</pub-id>
          <pub-id pub-id-type="pmid">28758992</pub-id>
        </element-citation>
      </ref>
      <ref id="B177">
        <label>177</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Puerarin induces molecular details of ferroptosis-associated anti-inflammatory on RAW264.7 macrophages</article-title>
          <source>Metabolites.</source>
          <year>2022</year>
          <volume>12</volume>
          <fpage>653</fpage>
          <pub-id pub-id-type="doi">10.3390/metabo12070653</pub-id>
          <pub-id pub-id-type="pmid">35888777</pub-id>
          <pub-id pub-id-type="pmcid">PMC9317776</pub-id>
        </element-citation>
      </ref>
      <ref id="B178">
        <label>178</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peng</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Micheliolide ameliorates renal fibrosis by suppressing the Mtdh/BMP/MAPK pathway</article-title>
          <source>Lab Invest.</source>
          <year>2019</year>
          <volume>99</volume>
          <fpage>1092</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="doi">10.1038/s41374-019-0245-6</pub-id>
          <pub-id pub-id-type="pmid">30976056</pub-id>
          <pub-id pub-id-type="pmcid">PMC6760645</pub-id>
        </element-citation>
      </ref>
      <ref id="B179">
        <label>179</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sulforaphane inhibits foam cell formation and atherosclerosis via mechanisms involving the modulation of macrophage cholesterol transport and the related phenotype</article-title>
          <source>Nutrients.</source>
          <year>2023</year>
          <volume>15</volume>
          <fpage>2117</fpage>
          <pub-id pub-id-type="doi">10.3390/nu15092117</pub-id>
          <pub-id pub-id-type="pmid">37432260</pub-id>
          <pub-id pub-id-type="pmcid">PMC10181211</pub-id>
        </element-citation>
      </ref>
      <ref id="B180">
        <label>180</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways</article-title>
          <source>Acta Pharm Sin B.</source>
          <year>2022</year>
          <volume>12</volume>
          <fpage>708</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.apsb.2021.10.005</pub-id>
          <pub-id pub-id-type="pmid">35256941</pub-id>
          <pub-id pub-id-type="pmcid">PMC8897044</pub-id>
        </element-citation>
      </ref>
      <ref id="B181">
        <label>181</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assini</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mulvihill</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Sutherland</surname>
              <given-names>BG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr<sup>-/-</sup> mice</article-title>
          <source>J Lipid Res.</source>
          <year>2013</year>
          <volume>54</volume>
          <fpage>711</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1194/jlr.M032631</pub-id>
          <pub-id pub-id-type="pmid">23269394</pub-id>
          <pub-id pub-id-type="pmcid">PMC3617945</pub-id>
        </element-citation>
      </ref>
      <ref id="B182">
        <label>182</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naringenin facilitates M2 macrophage polarization after myocardial ischemia-reperfusion by promoting nuclear translocation of transcription factor EB and inhibiting the NLRP3 inflammasome pathway</article-title>
          <source>Environ Toxicol.</source>
          <year>2023</year>
          <volume>38</volume>
          <fpage>1405</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1002/tox.23774</pub-id>
          <pub-id pub-id-type="pmid">36988289</pub-id>
        </element-citation>
      </ref>
      <ref id="B183">
        <label>183</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chao</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Weng</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Kao</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Naringenin more effectively inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in macrophages than in microglia</article-title>
          <source>Nutr Res.</source>
          <year>2010</year>
          <volume>30</volume>
          <fpage>858</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nutres.2010.10.011</pub-id>
          <pub-id pub-id-type="pmid">21147369</pub-id>
        </element-citation>
      </ref>
      <ref id="B184">
        <label>184</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis</article-title>
          <source>Bioengineered.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>10924</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1080/21655979.2021.1995994</pub-id>
          <pub-id pub-id-type="pmid">34699317</pub-id>
          <pub-id pub-id-type="pmcid">PMC8809912</pub-id>
        </element-citation>
      </ref>
      <ref id="B185">
        <label>185</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naringenin attenuates inflammation, apoptosis, and ferroptosis in silver nanoparticle-induced lung injury through a mechanism associated with Nrf2/HO-1 axis: In vitro and in vivo studies</article-title>
          <source>Life Sci.</source>
          <year>2022</year>
          <volume>311</volume>
          <fpage>121127</fpage>
          <pub-id pub-id-type="doi">10.1016/j.lfs.2022.121127</pub-id>
          <pub-id pub-id-type="pmid">36306867</pub-id>
        </element-citation>
      </ref>
      <ref id="B186">
        <label>186</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing</article-title>
          <source>Redox Biol.</source>
          <year>2022</year>
          <volume>56</volume>
          <fpage>102463</fpage>
          <pub-id pub-id-type="doi">10.1016/j.redox.2022.102463</pub-id>
          <pub-id pub-id-type="pmid">36108528</pub-id>
          <pub-id pub-id-type="pmcid">PMC9482117</pub-id>
        </element-citation>
      </ref>
      <ref id="B187">
        <label>187</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Quercetin alleviates ferroptosis accompanied by reducing M1 macrophage polarization during neutrophilic airway inflammation</article-title>
          <source>Eur J Pharmacol.</source>
          <year>2023</year>
          <volume>938</volume>
          <fpage>175407</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.175407</pub-id>
          <pub-id pub-id-type="pmid">36417973</pub-id>
        </element-citation>
      </ref>
      <ref id="B188">
        <label>188</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Quan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quercetin alleviates acute kidney injury by inhibiting ferroptosis</article-title>
          <source>J Adv Res.</source>
          <year>2021</year>
          <volume>28</volume>
          <fpage>231</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jare.2020.07.007</pub-id>
          <pub-id pub-id-type="pmid">33364059</pub-id>
          <pub-id pub-id-type="pmcid">PMC7753233</pub-id>
        </element-citation>
      </ref>
      <ref id="B189">
        <label>189</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ceria nanozyme coordination with curcumin for treatment of sepsis-induced cardiac injury by inhibiting ferroptosis and inflammation</article-title>
          <source>J Adv Res.</source>
          <year>2024</year>
          <volume>63</volume>
          <fpage>159</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jare.2023.10.011</pub-id>
          <pub-id pub-id-type="pmid">37871772</pub-id>
          <pub-id pub-id-type="pmcid">PMC11380017</pub-id>
        </element-citation>
      </ref>
      <ref id="B190">
        <label>190</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>β-caryophyllene acts as a ferroptosis inhibitor to ameliorate experimental colitis</article-title>
          <source>Int J Mol Sci.</source>
          <year>2022</year>
          <volume>23</volume>
          <fpage>16055</fpage>
          <pub-id pub-id-type="doi">10.3390/ijms232416055</pub-id>
          <pub-id pub-id-type="pmid">36555694</pub-id>
          <pub-id pub-id-type="pmcid">PMC9784863</pub-id>
        </element-citation>
      </ref>
      <ref id="B191">
        <label>191</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yi</surname>
              <given-names>ZH</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>SQ</given-names>
            </name>
            <name>
              <surname>Ke</surname>
              <given-names>JY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Baicalein relieves ferroptosis-mediated phagocytosis inhibition of macrophages in ovarian endometriosis</article-title>
          <source>Curr Issues Mol Biol.</source>
          <year>2022</year>
          <volume>44</volume>
          <fpage>6189</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="doi">10.3390/cimb44120422</pub-id>
          <pub-id pub-id-type="pmid">36547083</pub-id>
          <pub-id pub-id-type="pmcid">PMC9777460</pub-id>
        </element-citation>
      </ref>
      <ref id="B192">
        <label>192</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liensinine pretreatment reduces inflammation, oxidative stress, apoptosis, and autophagy to alleviate sepsis acute kidney injury</article-title>
          <source>Int Immunopharmacol.</source>
          <year>2023</year>
          <volume>122</volume>
          <fpage>110563</fpage>
          <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110563</pub-id>
          <pub-id pub-id-type="pmid">37392573</pub-id>
        </element-citation>
      </ref>
      <ref id="B193">
        <label>193</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of liensinine in sensitivity of activated macrophages to ferroptosis and in acute liver injury</article-title>
          <source>Cell Death Discov.</source>
          <year>2023</year>
          <volume>9</volume>
          <fpage>189</fpage>
          <pub-id pub-id-type="doi">10.1038/s41420-023-01481-3</pub-id>
          <pub-id pub-id-type="pmid">37353487</pub-id>
          <pub-id pub-id-type="pmcid">PMC10290152</pub-id>
        </element-citation>
      </ref>
      <ref id="B194">
        <label>194</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Jing-Fang n-butanol extract and its isolated JFNE-C inhibit ferroptosis and inflammation in LPS induced RAW264.7 macrophages via STAT3/p53/SLC7A11 signaling pathway</article-title>
          <source>J Ethnopharmacol.</source>
          <year>2023</year>
          <volume>316</volume>
          <fpage>116689</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jep.2023.116689</pub-id>
          <pub-id pub-id-type="pmid">37315642</pub-id>
        </element-citation>
      </ref>
      <ref id="B195">
        <label>195</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>MaiJiTong granule attenuates atherosclerosis by reducing ferroptosis via activating STAT6-mediated inhibition of DMT1 and SOCS1/p53 pathways in LDLR<sup>-/-</sup> mice</article-title>
          <source>Phytomedicine.</source>
          <year>2024</year>
          <volume>128</volume>
          <fpage>155489</fpage>
          <pub-id pub-id-type="doi">10.1016/j.phymed.2024.155489</pub-id>
          <pub-id pub-id-type="pmid">38569295</pub-id>
        </element-citation>
      </ref>
      <ref id="B196">
        <label>196</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kuang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction</article-title>
          <source>Biomed Pharmacother.</source>
          <year>2022</year>
          <volume>145</volume>
          <fpage>112367</fpage>
          <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112367</pub-id>
          <pub-id pub-id-type="pmid">34740097</pub-id>
        </element-citation>
      </ref>
      <ref id="B197">
        <label>197</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Traditional Chinese medication Tongxinluo attenuates lipidosis in ox-LDL-stimulated macrophages by enhancing Beclin-1-induced autophagy</article-title>
          <source>Front Pharmacol.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>673366</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2021.673366</pub-id>
          <pub-id pub-id-type="pmid">34248627</pub-id>
          <pub-id pub-id-type="pmcid">PMC8267176</pub-id>
        </element-citation>
      </ref>
      <ref id="B198">
        <label>198</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Guan</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Qing-Xin-Jie-Yu Granule inhibits ferroptosis and stabilizes atherosclerotic plaques by regulating the GPX4/xCT signaling pathway</article-title>
          <source>J Ethnopharmacol.</source>
          <year>2023</year>
          <volume>301</volume>
          <fpage>115852</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jep.2022.115852</pub-id>
          <pub-id pub-id-type="pmid">36272494</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
